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Abstract 
 
Background: 
 It has been reported that fucoidan, a polysaccharide commonly extracted from brown 
seaweeds, possesses a wide range of biological activities. Fucoidan is composed of a highly 
negatively charged and polydispersed oligosaccharides having fucose as the main component. 
It is not possible to separate various oligosaccharides of intact fucoidan using only one method 
because of their high negative charge, high molecular weight and polydispersity. Fucoidan is 
commercially available in the oral dosage form (only available as capsules). However, its 
bioavailability after oral administration is currently unknown. Therefore, the objective of this 
study was to develop an analytical technique that can measure the concentration of fucose (the 
main component of intact fucoidan) after oral administration of fucoidan. The application of 
newly developed method was demonstrated by analysing the fucose levels in patients’ plasma 
before and after oral administration of fucoidan. 
 
Method:  
Different types of chromatographic methods (reversed-phase chromatography, reversed-phase 
ion-pairing chromatography and normal phase chromatography) were tried to obtain a method 
that can separate fucose from other compounds present in plasma.  Once this was achieved, 
several analytical parameters such as mobile phase composition, buffer strength, pH, and other 
parameters within the detector were also tested to increase the sensitivity of the method. 
Digestion and precipitation methods were used to breakdown fucoidan into fucose and to 
precipitate fucose respectively. The developed method was then validated using inter- and 
intra-day precision, accuracy and reproducibility. The limit of detection (LOD) and limit of 
quantitation (LOQ) was also calculated using the mean standard deviation obtained from three 
 ix 
 
calibration curves. The developed and validated method was then used to determine the 
presence of plasma fucose levels in cancer patients before and after oral administration of 
fucoidan. The patients were taking either Docexatel (maximum dose between 75 and 100 mg 
every 3 weeks) or Anastrozole (1 mg daily). A 250 mg hard-gelatine capsule containing 187.5 
mg of fucoidan was orally administered four times a day for seven days. The patients’ plasma 
samples were precipitated with acetonitrile and digested using 20% trifluoroacetic acid to 
depolymerise fucoidan into fucose. The amount of fucose in the plasma samples was then 
determined using the developed method. 
 
Results: 
It was concluded that, although this might be limited to the particularly selected 
chromatographic parameters (types of column, mobile phase and ion-pairing reagents), normal 
phase chromatography was more suitable in the analysis of fucose compared to the reversed-
phase and reversed-phase ion-pairing chromatography tested in this study. The tested normal 
phase chromatography method performed well in retaining and resolving fucose both in 
standard solution and plasma samples. Fucose-containing plasma sample was resolved using 
Shodex Asahipak NH2P-50 4E column employed with a series of Dionex Ultimate Pump, 
autosampler, column compartment and a Charged Aerosol Detector (CAD). Mobile phase 
consisted of 5 mM ammonium acetate pH 4.75 and acetonitrile (20:80) with the flow rate of 
1.0 mL/minute. Peak to concentration correlation test using 5 different concentrations of fucose 
solutions (5 µg/mL to 100 µg/mL) gave exponential correlation coefficient (R2) of 0.9999. 
Fucoidan was digested using 20% trifluoroacetic acid and was found to contain 20.35%±0.87% 
(n=3) of fucose (w/w). Plasma protein and spiked fucoidan from 1 mL of plasma was 
precipitated using 4 mL of acetonitrile. Recovery of fucose in fucoidan-spiked blank plasma 
after precipitation was found to be more than 92% (n=2) based on the calculated fucose 
 x 
 
concentration. Intra- and Inter-day precision, accuracy and reproducibility values were found 
to be less than 5% RSD. Limit of detection (LOD) and limit of quantitation (LOQ) of the 
developed method was calculated to be 2.28 ng and 6.92 ng, respectively. Fucose concentration 
in patients’ plasma after the administration of fucoidan was elevated by (1.14±0.61) mg/100 
mL (n=19). This suggested that the oral absorption of fucoidan was around 14.28%±7.59% 
(n=19). 
 
Conclusion: 
The developed method was suitable for the detection of fucose in patients treated with oral 
fucoidan. The result obtained in this study showed that less than 15% of orally administered 
fucoidan was absorbed. Nonetheless, this shows that, to some extent, fucoidan is getting 
absorbed following oral administration. Moreover, the proposed method can be used in the 
analysis of fucoidan in human plasma as an alternative option to the currently available ELISA 
method or those using derivatisation. It offers simplicity in the procedure and specificity in the 
detection of fucose, the main component of fucoidan. 
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Chapter 1 -  Introduction 
1.1 Seaweeds 
Seaweeds, plant-like organisms, are the enrichment to the aquatic biodiversity and have been 
well recognised for its usefulness for ages. History of seaweeds dates back to early sixth century 
where Japanese emperors utilised seaweed as a kind of tax or processed and prepared it as food 
supplement1. Moreover, in the Far East region, seaweeds were used as traditional medicine for 
the treatment of several ailments including goitre2,3. Seaweeds were also used for other 
economic purposes including their supply as cattle fodder2,4. 
 
1.2 Classes of Seaweeds 
There are thousands of seaweed species and four major classes are shown in Figure 12,4. This 
classification is based on their thallus colour or pigmentation. These include Chlorophycaeae 
(green), Cyanophycaeae (blue-green), Rhodophycaeae (red) and Phaeophycaeae (brown) 
seaweeds. Among these four classes, Chlorophycaeae and Cyanophycaeae cover both salt or 
fresh water species while Rhodophycaeae and Phaeophycaeae are mostly salt water species. 
Seaweeds are structurally as well as functionally distinct to land plants. They do not have a 
complete or distinctive root and leaf system but some have bladders filled with air to help them 
float in the water2. They vary in size and appearance but their common natural living habitats 
are rock surfaces in coastal areas.  
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         (1)                                  (2)                                 (3)                                 (4) 
Figure 1.1 Pictorial representation of four major classes of seaweed: (1) Green seaweed Cladophora 
rupestris, (2) Red seaweed Asparagopsis armata, (3) Brown seaweed Fucus vesiculosus, (4) Brown 
seaweed Undaria pinnatifida 5 
 
The annual economic market of seaweeds in 2009 was recorded to be approximately                         
U.S. $ 5 billion worldwide6. It has also been reported that a US based company alone, selling 
commercial product of fucoidan (polysaccharide commonly extracted from brown seaweeds) 
claimed as a health supplement, has gained annual income of $6 billion in 20157. This shows 
an increasing trend in seaweeds market, particularly fucoidan. Seaweeds can offer potential 
resources to fulfil human need of carbon-based food since they are found in abundance in most 
coastal regions around the world. The trend has shifted from consuming food merely as the 
need to satisfy the taste-sense towards exploring both of their nutritional and medicinal value; 
hence seaweed can be considered as one of the valuable option. Numerous research studies 
have provided an insight on seaweed’s chemical components and biological activities8-13. 
 
1.3 Components of Seaweeds 
Seaweeds are known to contain multiple components such as polysaccharides, proteins, 
minerals and vitamins. Seaweeds are also considered as “functional food” because they carry 
components which also exert bioactive functions. For example, brown seaweeds such as 
Saccharia sp. and Undaria sp. contains alginic acid, an insoluble gelatinous carbohydrate, 
which is known to possess antibacterial, anti-hypertensive and anticancer properties11,14. On 
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the other hand, carrageenan from Chondrus crisprus consisting of a mixture of polysaccharides 
is known for its anticoagulant and antiviral properties. Alginate or alginic acid, carrageenan 
and agar are also commercially used as thickeners, emulsifiers, food supplement and other 
applications; such as the utilisation of agar as a raw material in capsule production for medical 
purpose and as a medium for cell cultures15,16. Polysaccharides, protein, minerals and vitamins 
are abundant in seaweeds but their composition and amount differ depending on the type of 
seaweed species, season of harvesting and location16. For example, the concentration of 
alginate extracted from Costaria costata in July is significantly higher compared to when it is 
extracted in April and May17. Also, it has been observed that calcium is produced higher by 
green seaweed than that by red or brown seaweeds8. Among several mineral components, 
fluoride is present in highest amount in brown seaweeds. Zinc, even though lesser in 
percentage, is higher than iron. The iron fraction in red seaweed is the highest while in brown 
seaweed it is the lowest. These mineral-rich seaweeds can be considered to be beneficial in 
providing mineral supplement for those suffered from mineral deficiency8. Seaweeds are also 
composed of polysaccharides, polymeric carbohydrate molecules composed of long chains of 
monosaccharide units bound together by glycosidic bonds. Fucoidan is one of the 
polysaccharide components found in seaweeds. 
 
1.4 Fucoidan 
It was Kylin, a professor of Uppsala University in Sweden, who first isolated fucoidan from 
Laminaria sp. and Fucus sp. species of brown seaweeds in 1913 and was initially named 
fucoidin based on the source of its isolation and later to fucoidan to conform with 
polysaccharide nomenclature18. Fucoidan is highly negatively charged, sulphated 
polysaccharide and exist only in brown seaweeds. The structure of fucoidan differs to the other 
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main type of polysaccharide from other classes of seaweeds such as Rhodophycaeae or red 
seaweeds, as it contains fucose as the backbone structure instead of galactose19. 
 
1.4.1 Sources 
Fucoidan is most commonly extracted from brown seaweed, although it can also be extracted 
from some marine invertebrates such as body wall of sea cucumbers or egg jelly coat of sea 
urchins18,20. It is widely spread in all species of brown seaweed but not in other classes of 
seaweeds such red seaweed, green seaweed and golden seaweed18. The chemical or structural 
composition of fucoidan varies according to the type of seaweed, season of harvesting, local 
climate and type of extraction method employed17,19.  Some brown seaweeds species, for 
example Fucus vesiculosus, have a relatively simple composition containing only fucose and 
sulphate groups; while fucoidan from Macrocystis pyrifera, Ecklonia kurome and Chorda filum 
are more complex with the addition of different monosaccharides20. 
 
1.4.2 Structure 
Till date there is no particular chemical structure of fucoidan has been established due to the 
variety of sources and many factors influencing the composition of fucoidan. Thus, the name 
fucoidan is directed towards general characteristics of the compound rather than a particular 
chemical structure (fucoidan composed of mainly fucose constitute the backbone of the 
structure and sulphate group attached to them creating branches). The term sulphated fucan in 
accordance to the IUPAC (International Union of Pure and Applied Chemistry) refers to a 
polysaccharide containing sulphated L-fucose with less than 10% (w/w) of other 
monosaccharides and the term fucoidan has been mainly used for seaweeds derived fucan18. 
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Percival et al. investigated the structure and composition of fucoidan obtained from four 
different species: Fucus vesiculosus, Fucus spiralis, Laminaria cloustoni and Himanthalea 
lorea19.  In this study; extraction with hot water, followed by alginate and protein removal with 
lead acetate, also with the addition of barium hydroxide; was used to obtain crude fucoidan. 
Hydrolysis of fucoidan using 0.5 N sulphuric acid for 3 hours was performed to obtain free 
fucose. It was found that, with the utilisation of polarimetric method, crude fucoidan from H. 
lorea contain 43.9% (w/w) fucose. The amount of fucose in H. lorea was the highest compared 
to Fucus vesiculosus, F. spiralis, and Laminaria cloustoni; with each of these samples contain 
41.2% (w/w), 35.8% (w/w), and 36.5% (w/w) of fucose respectively. Other components found 
to be sulphate and some metals residues (calcium, magnesium, sodium and potassium). This 
crude fucoidan was then purified through several steps; dissolution in water, evaporation and 
re-precipitation in alcohol. After hydrolysis, further analysis using quantitative paper 
chromatography showed that not only the percentage of major component of fucose increased 
to 79.1% (w/w); some other sugars such as galactose 7.2% (w/w), xylose 1.3% (w/w) and 
uronic acid 2.8% (w/w) were also observed and were regarded as impurities.  
 
Similarly, Schweiger et al. observed the existence of sugar or monosaccharide residues other 
than fucose in fucoidan. They extracted fucoidan from different species of seaweed. This study 
used Macrocystis pyrifera, a brown seaweed species, which is commonly utilised in the 
production of alginic acid or alginate. They found that, through filtration and crystallisation of 
L-fucose, the filtrate contained some portion of L-fucose and other components of sugars or 
acids. Galactose and xylose were observed through chromatographic technique, with also a 
small trace of mannose but no evidence of uronic acids21. Following methylation method and 
identification of methylated sugar after hydrolysis, they concluded that fucoidan is a fucan with 
mainly L-fucose residues linked by α-(12) glycosidic bonds and sulphate group attached in 
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the fourth position of L-fucose residues. There is also a possibility that every fifth fucose 
residue in the structure has a fucose branch attached on it19. This structure of fucoidan was 
accepted for almost 50 years before Patankar and colleagues offered a new structure and, they 
claimed, to be more probable structure. 
 
Patankar et al. concluded that the availability of tri-O-methyl-L-fucose in fucoidan molecule 
has a very high degree of branching22. This was different to the branching site suggested 
previously by Percival et al. which was to be fucose 4-sulphate. It was proposed that the core 
chain of fucoidan to be α-(13) linked fucose and substituted with sulphate group at C-4 
position of fucose. Results from sulphate analysis indicated that one sulphate group is present 
in the structure for every 3-4 mol of fucose (0.3 mol of sulphate/mol of fucose)22. These 
findings were similar to that observed by Ermakova and colleagues when attempted to 
determine the structure of fucoidan. It was suggested, based on the Nuclear Magnetic 
Resonance (NMR) analysis, that fucoidan from Sargassum hornery has a structure of α-L-
fucopyranose linked in 1,3 position with sulphate attached at position 2, while Costaria costata 
showed a more complex structure with existing residues of acetyl groups, methyl groups and 
galactopyranose. Fucose in Fucus vesiculosus fucoidan is also attached to the main structure 
creating a branched site of two to three fucose residues in the molecule11. The fucoidan 
structures as suggested by Percival (A) and Patankar (B) are shown in Figure 2. 
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Figure 1.2 The proposed structure of fucoidan23 
 
Different studies have also investigated the structure of fucoidan extracted from different 
seaweeds (summarised in table 1.1). It can be seen from the table that the structure of fucoidan 
and its compositions varies between one seaweed to another. This conclusion can be 
withdrawn, for instance, based on the results reported by Bilan et al. They extracted fucoidan 
from three different seaweeds: Saccharina latissima, Fucus serratus L.and Chordaria 
flagelliformis. The same fractionation method using anion-exchange chromatography and 
analysis using NMR spectroscopy were performed in all three studies. As shown in table 1.1, 
Fucus serratus derived fucoidan composed of L-fucose, sulphate and acetate with the molar 
ratio of (1:1:0.1), while that extracted from Chordaria flagelliformis was composed of L-
fucose, sulphate and D-glucuronic acid with the molar ratio of (1:1:0.25). 
 
The result of the studies listed in table 1.1 also suggested that there is a common structure of 
fucoidan observed in most of the investigated seaweeds disregard to the utilised degradation 
method. Fucoidan degraded with four different methods: fractionation using anion-exchange 
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chromatography, methylation, autohydrolysis and enzymatic hydrolysis; were identified to 
have the structure of 3-linked α-L-fucopyranose. This commonly exist L-fucose in fucoidan 
has been considered as a general characteristic in the identification of fucoidan as that also used 
by IUPAC as it is mentioned earlier in this chapter. 
 
Table 1.1 Structural properties of fucoidan from different seaweeds and extraction methods 
Source of 
seaweeds 
Structure of fucoidan and 
composition 
Extraction methods Reference 
Saccharina 
latissima 
3-linked α-L-fucopyranose 
 
6-linked β-D-galactopyranose 
 
4-linked β-D-glucopyranosyluronic acid 
and 2-linked α-D-mannopyranose 
 
3-linked β-D-glucopyranosyluronic acid 
Fractionation using Anion-
exchange chromatography with 
NMR spectroscopy analysis 
Bilan et al.24  
 
Fucus 
serratus L. 
3- and 4-linked α-L-fucopyranose 
residues 
 
→3)-α-L-Fucp-(1→4)-α-L-Fucp-(1→ 
 
Fucoidan composed of L-fucose, 
sulphate and acetate (1:1:0.1) 
Fractionation using Anion-
exchange chromatography with 
1D and 2D 1H and 13C  NMR 
spectroscopy analysis 
Bilan et al.25 
 
Chordaria 
flagelliformis 
3-linked α-L-fucopyranose 
 
α-L-Fucf-(1→2)-α-L-Fucf-(1→ 
 
Fucoidan composed of L-fucose,, 
sulphate and D-glucuronic acid 
(1:1:0.25) 
Fractionation using Anion-
exchange chromatography with 
1D and 2D 1H and 13C  NMR 
spectroscopy analysis 
Bilan et al.26 
 
Laminaria 
cichorioides 
(1→3)-type α-L-fucopyranose 
Autohydrolysis 
Anastyuk et 
al.27 
 
Analipus 
japonicus 
1→3)-linked α-L-fucopyranose Methylation, periodate oxidation 
coupled with NMR spectroscopy 
Bilan et al.28 
 
Fucus 
distichus 
→3)-α-L-Fucp-(2,4-di-SO 3 − )-(1→4)-
α-L-Fucp-(2SO 3 − )-(1→ 
 
Mostly disaccharides and no fucose 
nor other monosaccharides observed 
Enzymatic hydrolysis using 
enzyme fom mollusc Littorina 
kurila 
Bilan et al.29 
 
Ascophyllum 
nodosum 
Mostly α-(1→3)-linked fucosyl residues 
and a few α-(1→4) residues 
Methylation, Smith degradation 
coupled with FTIR and NMR 
spectroscopy analysis 
Marais et al.30 
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It has also been reported that there are two known types of fucoidan based on their 
glycosaminoglycan structure; F-fucoidan and U-fucoidan. F-fucoidan consists of more than 
95% sulphated ester of L-fucose in seaweeds, while U-fucoidan is composed of approximately 
20% glucuronic acid. The average molecular weight (MW) of fucoidan is also considered very 
high. Fucoidan from Hizikia fusiformae, for example, has an average molecular weight of 92.7 
kDa, while molecular weight of Fucus vesiculosus derived fucoidan varies between 100 to 217 
kDa and in Erylus discophorus found even higher of up to more than 2000 kDa15,20,31. 
 
1.4.3 Extraction and hydrolysing method 
More than 60 years ago, hot water was used to extract crude fucoidan from several seaweeds 
species. This was followed with the addition of sulphuric acid to remove and decompose alkali-
fucoidan complex. The alkali-fucoidan complex was filtered and acid was evaporated followed 
by precipitation of fucoidan using alcohol. Total of fucoidan yielded with this method was 
reported to be 79.1% of the dried sample as confirmed by quantitative paper chromatographic 
method19. Similar method employed isopropyl alcohol and methanol to extract fucoidan. A 
total of 110 g purified fucoidan was obtained from 330 g crude fucoidan. Fucose concentration 
in the purified fucoidan was 24.9% of the total sample and this was determined with the 
utilisation of oxidation reaction of fucose with Fehling solution21. Other methods used 0.03 M 
hydrochloric acid, papain, and a mixture of 4 M trifluoroacetic acid/methanol and water 
(4:2:1)15,32,33. It was reported that the amount of fucoidan yielded by each of these methods was 
2.9%, 3.2% average and 1.75% of the dry weight seaweeds respectively. 
 
Various techniques have been used to depolymerise or hydrolyse fucoidan into smaller 
molecular weight or structurally less complex oligosaccharides including chemical or 
enzymatic degradation. Attempts have been made to fractionate fucoidan from Ascophyllum 
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nodosum utilising ion-exchange displacement centrifugal partition chromatography. The 
separation was aided by running 0.025 M NaOH as mobile phase through a circular partition 
disk rotor column packed with ion-exchanger organic stationary phase of 10% solution of 
amberlite LA2 in methyl isobutyl ketone (MiBK). This method successfully fractionated 
fucoidan into smaller oligosaccharides with different molecular mass composition and 
sulphation pattern. The resulted low molecular weight (LMW) fucoidan was categorised into 
3 groups based on the average molecular size; 9.5 kDa, 7.9 kDa and 7.1 kDa34. Another 
technique utilised for the fractionation of fucoidan was gel filtration chromatography. Using 
this technique fucoidan was separated into two major fragments, one having crude fucoidan 
containing 52.8% fucose and another consisted of LMW sulphated polysaccharide with 57.4% 
galactose35. LMW fucoidan was also obtained using chemical or enzymatic degradation 
methods. Chemical degradation of fucoidan was performed using either with 10 mL of 0.05 M 
sulphuric acid at 105°C for 5 hours or 1.5 mL concentrated 12 M sulphuric acid at 30°C for     
1 hour which  produced LMW fucoidan oligosaccharides with an average molecular weight of 
43 kDa from the initial molecular weight of main sulphated polysaccharide of 680 kDa36. Other 
study used 2 M trifluoroacetic acid at 100°C for 7 hours to hydrolyse fucoidan and obtained 
oligosaccharides with average molecular weight ranged from 30 kDa to 80 kDa from the initial 
molecular weight of crude fucoidan of 710 kDa37. 
 
Depolymerisation of fucoidan was also carried out using fucoidanase enzymes which are 
commonly isolated from marine bacterium38. However, there are studies which utilised 
fucoidanase from sources other than marine bacterium for the degradation of fucoidan39. For 
instance, use of fucoidanase from sporophylls of Undaria pinnatifida, sea cucumber and 
Fusarium sp.33,40,41. Degradation of fucoidan using fucoidanase enzymes was thought to be 
more effective because they are known to cause site specific breakdown of linkage or bonding 
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in the fucoidan structure. Fucoidanase isolated from Flavobacterium sp., for example, was 
stable in a broad range of pH and able to degrade fucoidan resulting in low molecular mass of 
up to 1.3 kDa. The hydrolysates from enzymatic degradation of fucoidan were found to contain 
more than 98% of fucose42. Fucoidanase has also been isolated from a bacterium (which was 
then called as SW5) that inhabited mud in the water treatment facility of an alginate plant; 
which was added to 1 L of solution containing fucoidan from Pelvetia canaliculata and 20 mM 
Tris-HCl buffer [pH 7.5], 5 mM MgCl2, 5 mM CaCl2 and 50 mM NaCl. The degradation 
products were analysed by gas chromatography as well as high-performance anion-exchange 
chromatography (HPAEC) coupled with conductivity detection.  The structural 
characterisation of fucoidan degraded fragments was carried out using NMR technique. It was 
found that the degradation products of fucoidan were composed of a tetrasaccharide sequence 
with a repetition structure of two units α-13-L-fucopyranose-2-sulphate and α-14-L- 
fucopyranose-2,3-disulphate, with the possibility of a residue (either sulphate, xylose, fucose 
or sulphated fucose) attached at C-4 position of fucose in the main structure. It also contained 
a hexasaccharide unit with the same homologous series39. Some other fractionation methods of 
fucoidan have also been listed above in sub-chapter 1.4.2. 
 
1.4.4 Biological Activities 
1.4.4.1 Anticoagulant 
Seaweeds have been reported to be used for decades as a kind of traditional medicine and are 
thought to exert various biological activities such as anti-inflammation, antivirus, antibacterial 
properties and anticoagulant4,43-48. Fucoidan is known to be one of the polysaccharide 
components of seaweeds which is mainly composed of fucose. Therefore, in recent years, 
research focus is driven towards fucoidan to check whether or not fucoidan contains biological 
properties similar to seaweeds. One of the recognised biological properties of fucoidan is its 
 12 
 
anticoagulant effect which is similar when compared to other high molecular weight, sulphated 
polysaccharides, such as unfractionated heparin (UFH)43. Fucoidan extracted from Pelvetia 
canaliculata showed anticoagulant effect, in vitro, at the concentration of 10 µg/mL. Similar 
to UFH, the anticoagulant effect of fucoidan from Pelvetia canaliculata was found to be 
because of the inhibition of factor IIa and Xa in the presence of heparin cofactor II. The efficacy 
of fucoidan was reported to be similar to UFH and dermatan sulphate in potentiation of heparin 
cofactor II. The anticoagulant effect of fucoidan from Pelvetia canaliculata was also compared 
to commercially available fucoidan having five times higher molecular weight and it was found 
that this commercially available fucoidan had no or little anticoagulant effect. It was postulated 
that high molecular weight of commercially available fucoidan was thought to influence its 
anticoagulant effect43. 
 
1.4.4.2 Anti-inflammatory 
A study suggested that sulphated polysaccharide extracted from Sargassum hemiphyllum (at 
the concentration of 5 mg/mL) significantly inhibited the secretion of pro-inflammatory 
cytokines, including IL-1β, IL-6, TNF-α and nitric oxide (NO), from lipopolysaccharide 
activated macrophage. The mechanism as to how this fucoidan inhibited the release of those 
pro-inflammatory cytokines was thought to be caused by the presence of polyphenols that 
suppressed the nuclear BF-ĸB receptor activity44. 
 
1.4.4.3 Anti-Human Immunodeficiency Virus (Anti-HIV) 
The anti-HIV effect of Fucus vesiculosus derived fucoidan has also been studied. In a study, 
fucoidan oligosaccharides were obtained by running the crude fucoidan through a gel filtration 
chromatography and then the oligosaccharides were classified according to their molecular 
weights: high molecular weight, intermediate molecular weight and low molecular weight 
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oligosaccharide. Each high molecular weight and intermediate molecular weight 
oligosaccharide was further separated by anion exchange chromatography and then was tested 
for their anti-HIV effect. Some oligosaccharides inhibited both the activity of reverse 
transcriptase (RT) enzyme and syncytium formation while some of them only inhibited the RT 
enzyme but not the formation of syncytium. The anti-HIV effect was thought as the result of 
virus attachment to the CD4 receptor was blocked through the attachment of the highly 
negatively charged sulphate group to the basic V3 loop on the receptor. However, interestingly, 
this study also found that, the anti-HIV activity of fucoidan was not affected by the presence 
of absence of sulphate groups. These results suggested a possibility of a different mechanism 
by which these sulphated molecules displayed their anti-HIV effect47.  
 
Later, the anti-HIV effect was also studied and was found that the most probable active 
compounds are polysaccharides with high molecular weight (˃2000kDa)31. Fucoidan was also 
able to inhibit adipogenesis mediated reduction of acid binding protein (aP2), acetyl CoA 
carboxylase (ACC) and peroxisome proliferation-activated receptor γ (PPARγ) and mRNA 
levels49. In another study, the extract containing fucoidan from Fucus vesiculosus, obtained by 
sequential extraction utilising diluted hydrochloric acid, has been reported to possess 
antioxidant effect when tested with ferric reducing antioxidant power (FRAP) and this activity 
was found to be stronger compared to that of sulphated galactan from red or green seaweed36. 
 
1.4.4.4 Anticancer 
There are other biological activities of fucoidan that have also been studied and recognised, 
such as antitumor, immune-stimulatory, antibacterial, antiviral and anti-protozoan50. When 
introduced to the HCT 116 colorectal carcinoma cell line, Ascophyllum nodosum derived 
fucoidan (at the concentration of 1 mg/mL) alleviated the viability of HCT 116 colorectal 
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carcinoma cells. This effect was thought to be related to the ability of fucoidan in inducing 
apoptosis in cancer cells. Also, the activity was found to be dose dependent. For example, no 
significant apoptosis effect was observed when HCT 116 cells were treated with 300 μg/mL of 
fucoidan. However, this effect was evident in more than 57% of cells when treated with 1000 
μg/mL of fucoidan15. A similar effect was also exhibited by fucoidan extracted from 
Cladosiphon okamuranus which exerted antiproliferative and markedly cytotoxic effects on 
MCF-7 cells, a breast cancer cell line, in a dose-dependent manner. Treatment of MCF-7 cells 
with fucoidan resulted in accumulation of sub-G1 population, chromatin condensation and 
internucleosomal fragmentation of deoxyribonucleic acid (DNA) which are the characteristic 
of apoptotic cell death51.  
 
1.4.4.5 Anti-diabetic 
Another reported important biological activity of fucoidan is its effect in regulating blood sugar 
levels. This biological function has been studied but is still limited to in vitro or animal models. 
A study showed that, when administered to alloxan-induced diabetic mice, fucoidan  
significantly reduced the glucose levels which was partly related to an increase in insulin serum 
level. This effect was dose-related, as higher dose of fucoidan gave a larger reduction in glucose 
level52. In another study, LMW fraction of fucoidan, with an average molecular weight of           
7 kDa, was found to be effective in attenuating diabetic retinopathy in streptozotocin-induced 
diabetic mice53.  
 
1.4.4.6 Structure-related bioactivities 
This is, in some way, has been proven to be true. Similar to that of heparan sulphate and 
dermatan sulphate, glycosaminoglycans which contain sulphate group in their structure, 
biological activity (particularly on its anticoagulant property) of fucoidan is also influenced by 
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the amount of this sulphate group. Heparin sulphate and dermatan sulphate have shown that 
their antithrombotic activity is increased with increase in the number of sulphate groups. The 
resulphation method was aimed to produce a similar amount of sulphate group to that of heparin 
as a reference in observing the anticoagulant activity. Also, both antithrombotic and 
anticoagulant activities of these two glycosaminoglycans are based on the ability to catalyse 
the inhibition of thrombin and/or to inhibit the activation of prothrombin. The increased 
number  of sulphate groups has enhanced the catalytic effects on the inhibition of thrombin by 
heparin cofactor II in plasma54.  
 
Similarly, Ecklonia kurome derived fucoidan with different molecular weight and the degree 
of sulphation was tested for its inhibitory effect on thrombin-fibrinogen reaction and amidolytic 
activity of thrombin. An increased in the inhibitory effect and amidolysis of the protein in the 
presence of heparin cofactor II was observed as a result of the increase of molecular weight. 
However, these activities were reduced with the decreased sulphate content. Further test 
showed no change in the binding ability of fucoidan to fibrinogen with the change of molecular 
weight and sulphate content. They suggested that heparin cofactor II-mediated antithrombin 
activity of the fucoidan was not depending on both molecular weight and sulphate content55. 
 
1.4.4.7 Low molecular weight (LMW) Fucoidan 
Fucoidan is a branched polysaccharide with a very high molecular weight (HMW). It is 
composed of a highly negatively charged, polydispersed and unidentified oligosaccharides 
having fucose as the main component. Fucoidan has a high negative charge owing to the 
presence of sulphate groups.  Fucoidan is also a mixture of small, medium and HMW 
oligosaccharides. Therefore, the biological activities of not only HMW but also LMW 
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oligosaccharides of fucoidan have been investigated. Some have also studied the biological 
activities between LMW fucoidan and unfractionated fucoidan having HMW. 
 
High molecular weight oligosaccharides of fucoidan have been studied for their effects on 
attenuating N-nitrosodiethylamine-induced liver fibrosis. It has been found that these 
oligosaccharides exerted anti-fibrogenesis effect due to the down regulation of the transforming 
growth factor beta 1 and chemokine ligand 12 expression56. The influence of molecular weight 
on the anticoagulant effect was also observed and found that HMW fucoidan showed better 
anticoagulant effect in vitro while LMW fucoidan promoted a better effect in vivo57. A LMW 
fucoidan, extracted from Laminaria japonica,  was found to be hepatoprotective when given 
to liver injury-induced  CCl4 (Carbon tetrachloride) and D-galactosamine mice58. Another 
study compared the effectiveness of LMW fucoidan with calcium dobesilate against diabetic 
retinopathy in streptozotocin-induced mice as well as in a high glucose-promoted vascular 
endothelial growth factor (VEGF) cells. LMW fucoidan alleviated diabetic retinal 
neovascularisation likely through lowering hypoxia-inducible factor-1α (HIF-1α) and VEGF 
expressions53. 
 
Ermakova et al. investigated the structure-related activity of fucoidan using six different 
oligosaccharides of fucoidan extracted from three different species (Eclonia cava, Sargassum 
hornery and Costaria costata). The six extracted oligosaccharides were: ShF1 (sulphated 
fucan), ShF2 (non-sulphated fucan), ShF3 (sulphated rhamnofucan), EcF1 (sulphated 
rhamnogalactofucan), EcF2 (sulphated galactoglucofucan) and CcF1 (sulphated galactofucan). 
The effects of these oligosaccharides on the colony formation were investigated using human 
melanoma (SK-MEL-28) and colon cancer (DLD-1) cells. All the oligosaccharides but EcF2 
showed inhibition to colony formation. EcF2 showed 8% inhibition compared to ShF2 and 
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ShF3 which significantly inhibited the formation of colonies. It was considered that the effects 
were probably influenced by sulphate groups, monosaccharide residue ratio and type of sugar 
residues bonding11. 
 
Table 1.2 summarises various biological properties possessed by either LMW or HMW 
fucoidan from different sources of seaweeds. It can be seen from the table that fucoidan 
extracted from different seaweeds can exert similar bioactivities. For instance, anticancer effect 
was shown by fucoidan extracted from Turbinaria ornata and Ascophyllum nodosum. The 
active fraction of Turbinaria ornata derived fucoidan was suggested to be the LMW fucoidan 
with (1→3)-linked fucose residues while that extracted from Ascophyllum nodosum was HMW 
fucoidan with the MW of up to 420 kDa15,59. This suggested that both LMW and HMW 
fucoidan can exerts similar biological activities even when they extracted from different source 
of seaweeds. 
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Table 1.2 Fucoidan isolated from different seaweeds, biological activity and the proposed active 
structure 
 
Source of 
seaweeds 
Biological 
activity 
Types of 
the study 
The proposed active structure of 
fucoidan Reference 
Pelvetia 
canaliculata Anticoagulant In vitro 
LMW Fucoidan with 3- or 4-O-
sulphate-L-fucose unit (MW of 20±5 
kDa) 
Colliec et 
al.43 
Sargassum 
hemiphyllum 
Anti-
inflammatory In vitro 
Sulphated polysaccharides extract 
consisted of fucose, galactose, 
glucose, galactosamine, mannose, 
sorbitol and myo-inositol 
Hwang et 
al.44 
Fucus 
vesiculosus Anti-HIV In vitro 
Both sulphated R-O-SO3- and non-
sulphated structure of LMW fucoidan 
(MW of 10-20 kDa) 
Beress et 
al.47 
Erylus 
discophorus Anti-HIV In vitro 
HMW fucoidan extract with the 
polysaccharide content of up to 98% 
Esteves et 
al.31 
Eclonia cava 
Sargassum 
hornery 
Costaria costata 
Anticancer In vitro 
Non-sulphated fucan and sulphated 
rhamnofucan from S. hornery extract 
(both consisted of fucose and 
rhamnose residue) 
Ermakova et 
al.11 
Saccharina 
cichorioides Anti-tumour In vitro sulphated (13)-α-L-fucan 
Ermakova et 
al.60 
Turbinaria 
ornata Anticancer In vitro 
LMW fucoidan with (1→3)-linked 
fucose residues 
Ermakova et 
al.59 
Ascophyllum 
nodosum Anticancer In vitro 
Fucoidan extract (MW: 47 and 420 
kDa) consisted of fucose, galactose, 
xylose and sulphate groups. 
Foley et al.15 
Cladosiphon 
okamuranus Antivirus In vitro 
Sulphate groups and glucuronic acid 
of fucoidan Hidari et al.
61
 
Fucus 
vesiculosus 
Hepato-
protective In vivo 
HMW fucoidan consisted of fucose, 
galactose, xylose, uronic acid and 
sulphate groups 
Hong et al.45 
Cladosiphon 
okamuranus Anti-fibrotic In vivo HMW fucoidan (MW: 41.4 kDa) 
Nakazato et 
al.56 
Sargassum 
patens Antivirus In vitro 
HMW fucoidan (MW: 424 kDa) 
consisted of fucose, galactose, 
mannose, xylose, glucose and 
galactosamine 
Zhu et al.46 
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Beress et al. investigated the anti-HIV effect of fucoidan extracted from Fucus vesiculosus and 
concluded that there was probably no particular structure influencing the bioactivities of 
fucoidan. The investigated effect was shown by both the tested sulphated and non-sulphated 
fucoidan fractions47. This was similar to that reported by Ermakova et al. in a study 
investigating the anticancer effect of fucoidan from Eclonia cava, Sargassum hornery and 
Costaria costata. They suggested that both non-sulphated fucan and sulphated rhamnofucan 
exert anticancer activity. However, among the tested fucoidan fractions from the three 
seaweeds, only non-sulphated fucan and sulphated rhamnofucan extracted from Sargassum 
hornery showed the anticancer effect11. The results provided by these studies suggested that, is 
some cases, the biological activities of fucoidan is independent to its molecular weight or the 
existence of sulphate groups. However, in other cases, fucoidan extracted from a particular 
seaweed exerts a certain bioactivity while it is not observed from fucoidan extracted from 
another type of seaweed(s). 
1.4.5 Toxicology 
Different studies have determined its toxicological factor or safety. The Undaria pinnatifida 
derived fucoidan at a dose of 1000 mg/kg body weight was suggested to be safe in rats 
following 28 days of administration62.  Another clinical study showed that the oral 
administration of fucoidan (3 g daily) in healthy human volunteers did not show any significant 
adverse effects except the observed alteration in blood clotting time. However, this clotting 
time was still within the normal clinical range63,64. The effects of a more excessive ingestion 
of fucoidan (extracted from Mozuku seaweed) of up to 4.05 g daily, given to 20 subjects for    
2 weeks, had also been investigated. There were no reported adverse effects on the subjects’ 
health nor abnormalities observed in the abdominal, blood, urine and fecal states65. Therefore, 
orally administered fucoidan can be considered safe based on these studies.   
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1.5 Fucoidan Absorption: Uncertainty 
Nowadays, fucoidan is available commercially because of its biological effects for the 
management of various disorders. It has been reported that fucoidan is relatively safe when 
given 3 g daily for 12 days63. However, fucoidan has a HMW and therefore its absorption into 
the systemic circulation following oral administration is questionable. The extent of fucoidan 
(either HMW or LMW) being absorbed into the systemic circulation, still needs to be 
investigated. 
 
Physicochemical properties (such as molecular weight, pKa and lipophilicity) of a drug can 
influence its oral bioavailability. Along with physicochemical properties, there are several 
other parameters which can influence the bioavailability of a drug. These include solubility, 
gastric emptying, gastrointestinal pH and interaction of the drug either with food, mucus, GI 
enzymes or with other drugs. It is important to consider all these factors while investigating the 
systemic absorption of fucoidan. There are two things which have not been clearly determined 
regarding the absorption of fucoidan: the mechanism by which fucoidan is getting absorbed 
and whether or not it is degraded prior to the absorption, and the site or location in the 
gastrointestinal tract (GIT) for fucoidan to be absorbed. These create uncertainty in the 
absorption of fucoidan. 
 
1.5.1 Mechanism of Absorption 
Barthe et al. described four potential mechanisms that would help a drug to cross the epithelial 
cell layers in the GIT; passive diffusion through the membranes, carrier-mediated transport, 
endocytosis and paracellular transport. Most LMW lipophilic drugs cross the intestinal mucosa 
through passive diffusion and the absorption rate is proportional to the drug concentration and 
the surface area.  Some drugs also utilise carrier-mediated transport which involves interaction 
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between the drug and a transporter. This mechanism is facilitated through either active 
transport, mediated by the use of metabolic energy, or passive transport which is driven by the 
concentration of the drug. It is suggested that macromolecules uptake (such as polysaccharides) 
in mammalian cells occurs with the utilisation of endocytosis mechanism and involves the 
endocytocytic vesicles with lysosomes containing high degree of enzymatic activity66. 
Chondroitin sulphate, an acidic mucopolysaccharide with considerably HMW, was suggested 
to utilise this endocytosis transport67. Paracellular transport, in a different way, occurs when a 
drug crosses the epithelial cell through a tight-junction and passes between the cells. Although, 
this tight-junctions cover only 0.1% of the intestine area, some small hydrophilic solutes, such 
as nutrients and ions, are able to cross through this site68. It is also known that some compounds, 
such as sodium caprate, chitosan and N-trimethyl-chitosan hydrochloride derivatives, have the 
ability to enhance the absorption of considered poorly absorbable drugs like peptides, peptides 
analogs or other hydrophilic macromolecules on this paracellular route66,68. 
 
The specific route via which oral fucoidan is absorbed, if absorbed at all, from the GIT is still 
unclear. General thought would consider fucoidan cannot be absorbed due to its very high 
molecular weight and hydrophilic properties. However, by comparison to other compounds 
which have similar properties, such as heparin, would give a better understanding of the 
probable mechanism for fucoidan to get absorbed.  
 
Heparin and fucoidan are both highly sulphated polysaccharides. Heparin is recognised for its 
anticoagulant activity and is commonly given as a post-operative treatment to prevent deep 
vein thrombosis and pulmonary embolism69. Also, it is given to patients who undergo cardiac 
surgery using cardiopulmonary bypass, coronary angioplasty, vascular surgery and for patients 
with disseminated intravascular coagulation70. Heparin is categorised as glycosaminoglycan 
 22 
 
and is derived from animal tissues71. Heparin is highly sulphated with pentose-structured 
monosaccharide as the main backbone and this is similar to that of fucoidan. The main 
difference, other than the type of sugar-backbone is that fucoidan has a more complex structure, 
with more branching site attached to its fucose backbone and higher molecular weight, 
compared to heparin. Heparin is a linear polysaccharide and composed of repeating 
monosaccharide units with commonly contains 14-linked residues of uronic acid72.  
 
The desire in developing oral heparin is increasing as it is considered to be more convenient 
compared to parenteral administration. On the one hand, because of its high molecular weight, 
hydrophilic and highly negatively charged structure; it is thought that heparin cannot be 
absorbed after oral administration. However, some studies have reported observable biological 
activity of heparin such as its antithrombotic or anticoagulant activity following oral 
administration. For example, orally given heparin in a dose of 7.5 mg/kg showed 
antithrombotic effect in rats compared to the control subjects given saline73.  
 
In another study, UFH which was given via intraduodenal route in rats also showed detectable 
anti-Xa activity in systemic blood and this activity peaked within 10 minutes of 
administration74. This suggested a possibility of heparin being absorbed after oral 
administration. Further investigation by Costantini et al. and Hiebert et al. utilising 
radiolabelled heparin demonstrated that heparin at some extents was absorbed and well 
distributed in the GIT tissues as well as reached blood circulation73,74. Costantini used 125I-
labeled heparin and observed this radiolabelled heparin was well distributed in the GIT vessel 
wall. The radiolabelled heparin also quickly reached blood circulation. The peak concentration 
of 10.6% (w/w) of the given dose was detected in peripheral blood and achieved within                  
5 minutes after administration. Moreover, the radioactivity in portal blood was found to be 
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higher than peripheral blood after 10 minutes of drug was given and, they concluded, this in 
line with the expectation that radiolabelled heparin was absorbed via the GIT mucosa.  
However, still in the same study, the peak plasma radioactivity was found to be 10 times lower 
when heparin was given via intragastric method and thought to be caused by the poor 
absorption on this site74.  
 
Similar result also obtained in different study by Hiebert and colleagues. They utilised 14C-
labelled heparin and was given to rats through oral route. Radioactivity was measured using 
1H-Nucleus Magnetic Resonance (1H-NMR) spectroscopy to some collected specimens taken 
from parts of stomach, duodenum, jejunum, ileum, colon, lung, kidney, liver, and faeces. 
Radioactivity was observed in all of the specimens and suggested that radiolabelled heparin 
was readily distributed in the GIT vessels or gut tissues. Furthermore, although the 
concentration was 10- to 100-fold less compared to that in gut tissues, radioactivity was also 
observed in non-gut tissues. Total radiolabelled heparin detected in gut tissues reached an 
average of 31.1% compared to only 1.0% in non-gut tissues. The peak plasma concentration of 
radiolabelled heparin was achieved within 3 minutes after administration at 2.6% of the dose 
given73.  
 
The above studies conducted by Costantini et al. and Hiebert et al. presented the fact that 
heparin, despite its considered high molecular weight and negatively charged structure, was 
absorbed and distributed in the GIT tissues as well as reach blood circulation. Although the 
given drug was considered as derived heparin, both authors claimed either chemical and 
pharmacological properties of the radiolabelled heparin retained the original properties of 
heparin73,74. Nonetheless, it is also apparent from both studies that, although heparin is 
absorbed after oral administration, the total plasma concentration is very low. Hence, different 
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studies provided a formula to increase the absorption of oral heparin; one of which by the 
addition of other components carrying a function as absorption enhancer such as deoxycholic 
acid (DOCA), papain, Sodium N-[8-(2-Hydroxybrnzoyl)Amino] Caprylate (SNAC) and 
polyaminomethacrylate coacervates69,75-77. 
 
Fucoidan in many ways similar to heparin. Both fucoidan and heparin are polysaccharides 
constituted mainly with a particular monosaccharide, fucose for fucoidan and uronic acid for 
heparin, bound to one another with glycosydic bonding. They are highly negatively charged 
compounds as a result from the existence of sulphate structure attached to the main backbone 
creating branches. HMW is also one of the characterisics of fucoidan and heparin. Hence, these 
three similar characteristics between fucoidan and heparin could be considered as the starting 
point in predicting the fate of fucoidan after oral administration. 
 
The first thought arises questioning whether fucoidan is broken down in the GIT to produce 
smaller oligosaccharides or it retains its whole initial big molecular structure. The ability of 
fucoidan to retain its initial molecular structure can possibly rely on the strength of the 
glycosidic bond connecting its smaller mono- or oligosaccharides fractions. The strength of 
this glycosidic bond could be referred to a study by Kenneth et al. on the stability of heparin in 
acidic and basic condition using 0.1N hydrochloric acid and 0.1N sodium hydroxide78.  
 
Kenneth et al. utilised gradient polyacrylamide gel electrophoresis (PAGE) and staining 
method and observed a reduction in the molecular weight of heparin under these strong acid 
and basic test conditions. An increase in reducing-end product from heparin was confirmed by 
PAGE method to be resulted from the glycosidic linkage breakdown of heparin molecule under 
acidic environment. Still with the same method, under strong acid stress test, heparin lost some 
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degree of its sulfation level. Under acidic condition of 0.1N hydrochloric acid in 60 °C for 1000 
hours of treatment, heparin lost around 12% of its sulphate group from its molecule78.  
 
The in vitro test result reported by Kenneth et al. aligns with the finding that orally administered 
heparin was broken down into its smaller mono- or oligosaccharide. It was suggested that two 
pharmacological effects of heparin as being measured by thrombin activity and anti-factor Xa 
activity depend on its molecular size. While anti-factor Xa activity relates to the existence of 
fragments of heparin as small as pentasaccharide, thrombin activity is associated with 
oligosaccharides of at least tetradodecasaccharides. Since only anti-factor Xa activity was 
observed and no apparent thrombin activity following oral administration of heparin, this ended 
up to the conclusion that heparin was degraded to smaller fragments74,79.  
 
Still in the same study, Grabovac et al. tested two types of radiolabelled heparin, [3H]heparin 
and [35S]heparin, which was orally administered to rats. In regards to the type of isotope being 
used, [3H]heparin is heparin which only is labelled at the reducing end while [35S]heparin is 
evenly labelled throughout the molecule. The result showed that 10% recovery of radioactivity 
of [3H]heparin in the urine was lower compared to 17% for [35S]heparin. This strengthened the 
conclusion to the occurrence of degradation of heparin in the GIT; as if particular fragments of 
heparin were released into the systemic blood circulation, only the reducing end of [3H]heparin 
would be radiolabelled but the fragments generated by [35S]heparin would always be 
radiolabelled79.  
 
Taking into consideration the result of the studies conducted by Kenneth at al. and Grabovac 
et al., fucoidan can also undergoes glycosidic bond cleavage in acidic gastric environment. 
This will cause fucoidan to subsequently lose some of its negative charge due to desulfation 
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and to produce smaller oligosaccharides and increase the possibility of absorption to occur. 
However, an important thing to note that, unlike heparin, fucoidan is not a linear in structure. 
It is more complex with higher degree of branches and higher molecular size. These factors 
can possibly hamper or at least minimise the effect of the degradation and desulfation caused 
by gastric acid.  
 
Another important factor with the ability to degrade fucoidan into its smaller oligosaccharide 
is α-L-fucosidase enzyme which exists in the body. This enzyme could be found everywhere 
in human tissues and body fluids and has a role in catalysing the release of L-fucose from 
simple or complex polysaccharides80. However, similar to the influence of gastric acidic 
environment to fucoidan; the activity of this enzyme in degrading orally-given fucoidan to 
produce smaller oligosaccharides is yet to be determined. 
 
The only available information about the absorption of oral fucoidan is those reported by Tokita 
et al. and Irhimeh et al. in their study63,81. Tokita et al. claimed the orally given fucoidan 
detected in plasma sample was remained unchanged. They utilised size exclusion 
chromatography with refractometry index detector (SEC-HPLC-RI) to compare the molecular 
weight of the given fucoidan to that detected in plasma and urine. They found out, the molecular 
weight of fucoidan in plasma was relatively the same to the administered fucoidan while in 
urine it was smaller. They then concluded that fucoidan was possibly degraded in secretory 
system but not in the intestine81.  
 
Irhimeh et al. in a similar study also confirmed the likelihood that fucoidan was not degraded 
following oral administration before it is absorbed into systemic blood circulation63. Tokita and 
Irhimeh also used Enzyme-linked Immunosorbent Assay (ELISA) method to detect fucoidan 
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in the plasma. Both studies confirmed that fucoidan was absorbed following oral 
administration. However, very low concentration of fucoidan detected in plasma; 0.6% of the 
given dose observed by Irhimeh while Tokita observed the plasma concentration of fucoidan 
to be 100 to 1000 times lower. They argued that this discrepancy occurred due to the different 
dose of oral fucoidan given in both studies, 3 times of 1 g fucoidan a day for 12 days and 1 
time for 1 day respectively. Fucoidan concentration in plasma reached its peak after 6 to 9 
hours after administration while in urine after 3 to 6 hours of administration81. 
 
Both studies by Tokita and Irhimeh showed a promising results indicating fucoidan, as it is 
heparin, is absorbed after oral administration. However, the fact that they suggested fucoidan 
was not broken down in the GIT, which is on the opposite to that of heparin, sparks questions. 
While this could be true and align with the thought that the higher molecular weight and more 
complex structure of fucoidan, compared to heparin, would probably limit the effect of enzyme 
and gastric acid environment to degrade its structure; some factors in these studies worth to get 
attention.  
 
The first thing to note with regards to the absorption of fucoidan based on the result reported 
by Irhimeh et al. and Tokita et al. is the conclusion suggesting that orally given fucoidan 
retained its structure following absorption in the GIT. This was determined by comparing the 
molecular weight of the given fucoidan to that detected in plasma and urine sample. SEC-
HPLC was used to determine the molecular weight of fucoidan. The molecular weight of 
fucoidan in the plasma was 55-96 kDa and in urine was much smaller with 1.8-3.1 kDa, while 
the orally administered fucoidan was 66 kDa in molecular weight81. It is understandable that 
the method was not able to determine the exact molecular weight of fucoidan; hence it is 
showed in average or range value of molecular weight. This could be caused by the fact that 
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fucoidan is a polydispersed molecule, without an exact entities. However, it also showed the 
lack of ability of this method to determine whether the lower detected molecular weight of 
fucoidan was caused by the polydispersed property of this molecule or due to the loss of some 
fractions from the structure.  
 
Secondly, the fractionated fucoidan as a result from the SEC-HPLC method was then 
determined using ELISA for fucoidan structure detection. Given the understanding that the 
antibody in ELISA will only recognise particular part of the molecule of fucoidan, the loss of 
other fractions from the molecule will not be detected. For example, the utilised fucoidan 
antibody by Tokita was expected to react with the polymeric structure of fucose in fucoidan81. 
Hence, this antibody will only recognise and react with fucose fraction in fucoidan. It will not 
recognise or consider, for example, the existence of sulphate group attached to the structure to 
give the detection. As a result, even with the loss of this sulphate fraction from the molecule, 
the method would still give the detection of fucoidan. This could be the down side given by 
this method since desulfation, the loss of sulphate group as it occurs to heparin, would also 
possibly occur to fucoidan in the GIT. The method can also interact with endogenous fucose. 
Therefore, it also can probably interact with endogenous heparin and other polysaccharides.  
 
Third, both studies by Irhimeh and Tokita focused on determination of the absorption of 
fucoidan following oral administration. There were no further attempts to include 
determination on the particular expected pharmacological effects of fucoidan, such as 
anticoagulant effect, which could also be used as confirmation to the absorption to occur. Some 
studies indicating the relation between the structural characteristics of fucoidan such as the 
molecular size and sulphate group with its biological properties. For example, molecular size 
of fucoidan was found to influence its anti-HIV activity of fucoidan31. In another study, the 
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branched structure of fucoidan (characterised with the existence of sulphate group and 
glycosidic bonds) showed to play an important role in achieving effective interaction with the 
complement protein which is a common mechanism for a drug to produce its pharmacological 
effects82. Measuring the pharmacological outcome as a part of determining the absorption of 
fucoidan could provide supporting evidence in taking the conclusion whether or not fucoidan 
is being absorbed, due to the correlation between the structure and its pharmacological 
activities as mentioned above.  
 
The conclusion made by Tokita et al. and Irhimeh et al., suggesting fucoidan is not degraded 
into smaller oligosaccharide after oral administration, could be true based on their study. 
However, a further study would help to provide more evidence to support this conclusion. This 
is because the conclusion was on the opposite to that of heparin which in some studies has been 
showed to be fractionated into smaller oligosaccharide in the GIT. The matter of fact, fucoidan 
has structure similarities with heparin. 
 
Another important factor on the absorption of oral fucoidan is the mechanism taken to cross 
the intestine barrier and reach the systemic blood circulation. There were no clear explanations 
in the available studies on fucoidan about this. Nonetheless, it was suggested that fucoidan 
possibly utilised the endocytosis mechanism similar to that was suggested for chondroitin 
sulphate63,67. Further studies, however, are still needed to support this conclusion.  
 
1.5.2 Site of absorption 
It was reported that orally administered fucoidan need longer time to reach blood circulation; 
3 hours for fucoidan compared to 5 minutes for heparin74,81. The peak plasma concentration 
was also very low; 0.6% (w/w) of the given dose when it was given 3 times of 1 g fucoidan a 
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day for 12 days63. Plasma concentration of the orally given heparin, though also very low of 
up to 10.6% (w/w) of the given dose, was higher compared to that of fucoidan74. Nevertheless, 
these studies have showed fucoidan is absorbed in the GIT. Unfortunately, there was no further 
information provided as to which mechanism play a role in the absorption of fucoidan and on 
which part in the GIT fucoidan is getting absorbed. Similar approach could reasonably be 
taken, to the available studies on heparin, to possibly predict the mechanism of fucoidan 
absorption and the site of absorption in the GIT. 
 
Orally administered heparin has been proven to be absorbed in the GIT. Although the amount 
of the absorbed heparin detected in plasma was low, it was very well distributed in the cell 
walls or epithelium of the intestine prior to the absorption73,74. The absorption of heparin 
occurred either through gastric cell walls and the intestine73. The influence of molecular weight 
and pH to the heparin movement through gastric mucosa has also been studied. It was found 
that the molecular weight of heparin and pH in the gastric play important role to the amount of 
heparin being absorbed71.  
 
Two different types of heparin, unfractionated heparin (UFH) which is considered to have high 
molecular weight and LMW heparin (LMWH) with lower molecular weight, was tested for 
their absorption in the gastric of rats subject. As the pH was changed between pH 7.4 and pH 
4.0, both UFH and LMWH showed different behaviour regarding its absorption through the 
gastric mucosa. The unfractionated heparin was suggested to easily cross the barrier in more 
acidic environment while LMWH was on the opposite. Bigger molecular size of the UFH was 
thought to prevent ionisation at acidic pH compared to LMWH and made it easier to cross the 
gastric mucosa. On the other hand, acidic environment from the lower pH gave less influence 
to the LMWH due to its lower molecular size. This also was applicable in the opposite way 
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when the test was done in basic environment at pH 7.4. Another factor influencing the degree 
and time of absorption of heparin, as suggested by Moazed et al. the author of the study, is the 
binding interaction between heparin with protein and cells in the mucosa. Compared to 
LMWH, UFH can interact with varieties of proteins. This will then prolong the time for UFH 
to remain stay in the luminal mucosal membrane before it is released to serosal side and 
probably reach the systemic circulation71. 
 
Taking the result of the study reported by Moazed et al. into consideration, fucoidan can also 
probably be absorbed through both gastric mucosa and the intestine. If similar result on heparin 
is also applied to fucoidan, there is a chance for fucoidan to get absorbed via gastric mucosa 
due to its very high molecular weight which was suggested to influence absorption in that site. 
Also, the possibility of the high interaction between fucoidan with protein and cells in mucosal 
membrane can give the answer to the lower plasma concentration and the longer time needed 
by fucoidan to reach blood circulation. However, this conclusion is made by the assumption 
that structural similarities between fucoidan and heparin will probably also give similar figure 
of its absorption in the GIT. Further study on fucoidan itself is needed to get the exact result. 
 
1.6 Aims and Objectives 
Interest in using fucoidan as a medication agent to deal with certain types of illnesses is 
increasing since it has been proven that fucoidan exerts particular biological activities. 
Fucoidan is used orally. However, no substantial evidence suggest that it is absorbed after oral 
administration. Some studies, using ELISA method, have suggested that it is absorbed. 
Additionally, other data showing fucose level in healthy and malignancy condition is also 
available. However, the utilised method had some problems such as cross-reaction as has been 
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mentioned above. Therefore, the objectives of this study are to develop a method which can 
determine the absorption of fucoidan and include 
1. development and validation of a method capable in detecting and quantifying fucose 
level in the plasma 
2. development of an extraction method to extract fucoidan from patients’ plasma sample 
and a digestion method to breakdown fucoidan into fucose 
3. analysis and quantification of fucose level in the patients’ plasma samples using the 
developed method 
 
It is expected that the result of the research will give a valuable data about the absorption profile 
of fucoidan in the GIT following single oral dose administration. This data is important to 
determine whether or not fucoidan or its fraction is absorbed. An evidence of increasing fucose 
level in the plasma will be considered that fucoidan probably undergoes digestion mechanism 
in the GIT that breaks fucoidan into its smaller fractions and then absorbed and passed through 
to the blood circulation. Also, the developed method will offer accuracy, sensitivity and 
validity in analysing fucoidan in plasma samples. 
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Chapter 2 - Materials and Methods 
2.1 Materials and Instrumentation 
2.1.1 Reagents 
Unless otherwise specified, this study used HPLC grade Acetonitrile (ACN) which was 
purchased from ThermoFischer Scientific (Waltham, MA, USA). Water was purified with 
Milli-Q water purifying system with equipped ultraviolet lamp DirectQ UV3 and was filtered 
through 0.22 MilliPack filter from Millipore (Bedford, Massachusetts, USA). L-(-)-fucose,      
D-(-)-fructose, D-(+)-glucose, D-galactose and D-xylose were purchased from Sigma Aldrich 
(Castle Hill, New South Wales, Australia). Trifluoroacetic acid (TFA), Ammonium sulphate, 
ethanol (EtOH) and acetic acid were of analytical grade and purchased from Sigma Aldrich 
(Castle Hill, New South Wales, Australia). Protamine sulphate was obtained from Sandoz 
(Boucherville, Quebec, Canada). Ammonium acetate was purchased from Fluka (Castle Hill, 
New South Wales, Australia. Undaria pinnatifida fucoidan (batch number UPF2012550) was 
obtained from Marinova Pty Ltd (Hobart, Tasmania, Australia) and was claimed to contain 
87.2% fucoidan based on its Certificate of Analysis (COA). Blank plasma was obtained from 
Royal Hobart Hospital and Red Cross (Hobart, Tasmania, Australia). 
 
2.1.2 HPLC instrumentation 
Unless stated otherwise, a series of Dionex Ultimate 3000 RS HPLC instrument modules from 
Dionex (Sunnyvale, CA, USA) was utilised. A Dionex Ultimate 3000 RS pump with an internal 
degasser was used to pump and automatically mix mobile phase from separate chambers. 
Samples were auto-injected and the temperature was constantly maintained with a Dionex 
Ultimate 3000 RS Autosampler. A Dionex Ultimate 3000 RS Column Compartment was 
employed to keep the column at a stable temperature.  The analyte of interest (fucose) was 
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detected using a Dionex Corona Ultra RS Charged Aerosol Detector (CAD). A Dionex Diode 
Array Detector and UV-Vis detector were also used during different methods trial. Chromeleon 
7 Chromatography Data System was also used to control the operations of the instrument and 
to run data acquisition. Instrument diagram is shown in Figure 2.1. 
 
2.1.3 Other instruments 
A vacuum evaporator, miVac (Genevac Ltd, Suffolk, UK), was utilised to evaporate the plasma 
samples. Evaporation mode was set to H2O mode and temperature was maintained at 30 °C. 
The pH of the mobile phase was read using pH-meter EZDO PL-600 series which has been 
calibrated at the pH of 4.01, 6.83 and 9.01 with the appropriate buffer solutions each time 
before its use. A heating block, brand Multi-block, from Lab-line (Thermo Fisher, Waltham, 
MA, USA) was utilised during the digestion of samples. When necessary, samples were also 
mixed using Lab-line Super-mixer vortex equipment and underwent centrifugation using a 
Sky-line ELMI-6M centrifuge (ELMI, Riga, Latvia). 
 
 
 35 
 
 
Figure 2.1 High Performance Liquid Chromatography Instrumentation 
 
2.2 Experimental procedures 
2.2.1 Sample preparation 
2.2.1.1Preparation of Standard solutions 
All the standard solutions were prepared by dissolving monosaccharides (fucose, glucose, 
fructose, xylose or galactose) with MilliQ water in a 10 mL separate volumetric flask. Each 
monosaccharide (10 mg) was weighted and transferred into a volumetric flask. Into this flask, 
5 mL of MilliQ water was added. The flask was then kept in an operating ultra-sonic bath for 
10 minutes or until the monosaccharide was completely dissolved. Subsequently, more water 
was added into the flask to make the total volume to be exactly 10 mL. The final concentration 
of each standard solution was 1 mg/mL and considered as the stock solution. Standard solution 
containing, 5, 10, 25, 50 or 100 µg/mL of each monosaccharide was made from this stock 
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solution through serial dilution using MilliQ water. This solution was prepared in triplicate and 
analysed once for each concentration. 
 
2.2.1.2 Blank plasma sample 
Blank plasma (500 µL) was taken and transferred into a 15 mL Corning (Corning, New York, 
USA) polypropylene centrifuge tube. This plasma was then precipitated using either 
ammonium sulphate, ethanol, 80% acetonitrile or acetonitrile as described below (2.2.3). The 
supernatant was carefully taken and discarded while the precipitate was kept intact. Then the 
digestion of precipitates was carried out using one of the three digestion solutions: concentrated 
sulphuric acid, 2M TFA or 20% TFA. Into the tube containing precipitate, the digestion 
solution was added and digestion was performed as described below (2.2.4). Subsequently, the 
mixture was evaporated to dryness with a vacuum evaporator. Milli Q water (1 mL) was then 
added into the dried sample, vortex-mixed for 1 minute and centrifuged at 3500 rotation per 
minute (rpm) for 20 minutes. The supernatant was taken and subjected to HPLC analysis. Each 
sample was prepared in duplicate and analysed in triplicate.  
 
2.2.1.3Fucose-spiked plasma 
The fucose standard solution was made by diluting 1 mL of fucose stock solution (1 mg/mL) 
with 9 ml of MilliQ water to obtain final volume of 10 mL. Plasma (500 µL) was pipetted and 
transferred into a 15 mL centrifuge tube. This plasma was then subjected to precipitation using 
the precipitation chemicals listed above. The supernatant was carefully taken and discarded 
while the precipitate was kept intact. Into the tube containing precipitate, 10, 20 50, 100, 200, 
400 or 800 µL of fucose solution (100 µg/mL) was added to obtain final mixture containing 1, 
2, 5, 10, 20 40 or 80 µg of fucose. The mixture was then evaporated to dryness. The dried 
sample was then subjected to digestion using the digestion chemicals described above. 
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Subsequently, the mixture was again left to evaporate to dryness in a vacuum evaporator. 
MilliQ water (1 mL) was then added to the dried sample, vortex-mixed for 1 minute and 
centrifuged at 3500 rpm for 20 minutes. The supernatant was taken to be analysed with the 
HPLC. Each sample was prepared in duplicate and analysed in triplicate.  
 
2.2.1.4Fucoidan stock solution 
Undaria pinnatifida extract powder (10 mg) was weighted and transferred into a 10 mL 
volumetric flask. Into this flask, 5 mL of MilliQ water was added and then sonicated using an 
operating ultra-sonic bath for 15 minutes or until all the powder was completely dissolved. 
MilliQ water was added into the tube to adjust the volume to 10 mL. This solution was 
considered as the fucoidan stock solution.  
 
2.2.1.5Quality control sample 
Blank plasma (500 µL) was taken and transferred into a 15 mL centrifuge tube. This plasma 
sample was then precipitated as described above. The supernatant was then completely taken 
and discarded while the precipitate was kept intact. Into the tube containing precipitate,            
200 µL of fucoidan stock solution was added. This mixture was then underwent evaporation to 
dryness. This dried sample was then subjected to digestion as described above. Subsequently, 
the mixture was again left to evaporate to dryness in a vacuum evaporator. The dried sample 
was then dissolved with 1 mL of MilliQ water, vortex-mixed for 1 minute and centrifuged at 
3500 rpm for 20 minutes. The supernatant was taken and considered as the final solution to be 
analysed with the HPLC. Each sample was prepared in duplicate and analysed in triplicate.  
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2.2.2 Solubility tests 
The solubility of fucose and fucoidan in different solvents; ethanol, 80% acetonitrile, 
acetonitrile, acetone and ammonium sulphate; was investigated. Fucose and fucoidan powder 
and solution was mixed with 1, 2, 3, 4 or 5 mL of each of the solvents. The solubility was 
determined by visual observation of whether or not fucose or fucoidan precipitated after 
addition of the solvent. 
 
2.2.3 Precipitation methods 
2.2.3.1 Precipitation using ammonium sulphate 
Precipitation of plasma protein using ammonium sulphate was tried in two consecutive steps. 
The first step was done by adding ammonium sulphate saturated solution into the plasma and 
the second by adding ammonium sulphate crystal.  
 
The ammonium sulphate saturated solution was prepared, in the laboratory, by dissolving 
ammonium sulphate with Milli-Q water. A glass beaker was filled with 200 mL of water and 
kept on an operating magnetic stirrer. Ammonium sulphate crystal was slowly and gradually 
added into the beaker until when the further added ammonium sulphate was not dissolved. 
 
Ammonium sulphate saturated solution (500 µL) was added into a centrifuge tube containing 
an equal volume of blank plasma. The mixture was then vortex-mixed for 1 minute and then 
centrifuged at 3500 rpm for 15 minutes. The supernatant (500 µL) was taken and transferred 
into a 15 mL centrifuge tube. Into this tube, 100 mg of ammonium sulphate powder was added, 
vortex-mixed for 1 minute and again centrifuged at 3500 rpm for 15 minute. The supernatant 
was carefully taken and considered as the final solution to be analysed with HPLC. 
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2.2.3.2 Precipitation using ethanol 
Plasma protein precipitation using ethanol was tried using two different methods. The first 
method was referred to the work which was conducted by Subhash et al. using 95% ethanol83 
and the second has been previously done by Jianguo et al. utilising cold absolute ethanol84.   
 
After using different composition of blank plasma and 95% ethanol (1:1, 1:2, 1:3, 1:4 and 1:5 
part volume of plasma to ethanol, respectively) it was found that the best precipitation was 
achieved using 1 volume of plasma and 4 volumes of ethanol. Therefore, blank plasma (1 mL) 
was taken and transferred into a 15 mL centrifuge tube. Into this tube, 4 mL of 95% ethanol 
was added, vortex-mixed for 1 minute and then centrifuged at 3500 rpm for 20 minutes. The 
supernatant was then taken and subjected to HPLC analysis. Each sample was prepared in 
duplicate and analysed in triplicate.  
 
On the other hand, precipitation using cold ethanol was done by adding 11 mL of cold absolute 
ethanol (previously stored in 4 °C fridge) into 1 mL of blank plasma. The mixture was then 
vortex-mixed and stored at -20 °C overnight. Subsequently, the mixture was centrifuged at 
3500 rpm for 20 minutes. The supernatant was then taken and analysed with HPLC. Each 
sample was prepared in duplicate and analysed in triplicate.  
 
2.2.3.3 Precipitation using 80% acetonitrile 
In this method the plasma proteins from one part of blank plasma was precipitated using four 
parts of 80% acetonitrile. Plasma (1 mL) was taken and transferred into a 15 mL centrifuge 
tube. Into this tube, 4 mL of 80% acetonitrile was added, vortex-mixed for 1 minute and then 
centrifuged at 3500 rpm for 1 minute. The supernatant was then taken and subject to HPLC for 
the analysis. Each sample was prepared in duplicate and analysed in triplicate.  
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2.2.3.4 Precipitation using acetonitrile 
In this method, the plasma protein was precipitated using acetonitrile. Blank plasma (500 µL) 
was transferred into a 15 mL centrifuge tube. Into this tube, 2 mL of acetonitrile was added, 
vortex-mixed for 1 minute and then centrifuged for 20 minutes at the speed of 3500 rpm. The 
precipitate was kept and the supernatant was discarded. 
 
2.2.4 Digestion method for plasma protein precipitate 
The following methods were tested in the digestion of plasma protein precipitate. 
 
2.2.4.1 Digestion using Sulphuric acid 
Protein precipitate obtained from precipitation step was digested with concentrated sulphuric 
acid as has been described previously85. Sulphuric acid (1 mL) was added into a glass vial 
containing protein precipitate. The vial cap was tightly closed and sealed with paraffin film.  
Using a heating block with the temperature of 100 °C, this vial was heated for 2 hours. The 
mixture was then evaporated to dryness.  Subsequently, 1 mL of MilliQ water was added into 
the dried sample and vortex-mixed for 1 minute. The mixture was then filtered using 0.22 µm 
syringe filter (Phenomenex, Lane Cove, NSW, Australia) and the filtrate was collected and 
subjected to HPLC analysis. 
 
2.2.4.2 Digestion using 0.2M trifluoroacetic acid 
TFA (0.2M, 3 mL) was added into a centrifuge tube containing protein precipitate obtained 
from precipitation stage using the method describe previously86. The tube’s cap was tightly 
closed and sealed with seven to eight layers of paraffin film. Using a heating block, the tube 
was heated at 100 °C for 6 hours. The mixture was vortexed every 1 hour. After heating for 6 
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hours, the mixture was kept on open bench for at least 30 minutes. Once it reached the room 
temperature, the mixture was evaporated to dryness using a vacuum evaporator. Each sample 
was prepared in duplicate and analysed in triplicate.  
 
2.2.4.3 Digestion using 20% trifluoroacetic acid  
Digestion of glycoproteins was also performed  using 20%(v/v) TFA  as described previously87. 
TFA (3 mL of 20%) was added into the tube containing protein precipitates obtained from the 
precipitation step using acetonitrile as described in 2.2.3.4. The tube’s cap was then tightly 
closed and sealed with seven to eight layers of paraffin film. Subsequently, the tube containing 
mixture of glycoprotein and 20% TFA was put on a heating block and heated at 100 °C for       
6 hours with vortexed mixing every 1 hour. Then, it was kept on open bench until it reached 
room temperature. A vacuum evaporator was then used to evaporate the solution to dryness. 
 
2.2.5 Digestion method for fucoidan 
The following methods were tested in the digestion of fucoidan. 
 
2.2.5.1 Digestion using 0.2M trifluoroacetic acid 
Digestion of fucoidan was performed using 0.2M TFA as described previously86. Fucoidan   
(15 mg) was weighted, transferred into a 20 mL volumetric flask. MilliQ water (10 mL) was 
added, then underwent sonication for 15 minutes or until fucoidan was completely dissolved. 
MilliQ water was then added to volume and thoroughly mixed. The solution (1 mL) was taken 
and transferred into a 15 mL centrifuge tube and was evaporated to dryness. TFA (0.2 M, 3 
mL) was added into the dry sample. The tube’s cap was tightly closed and sealed with seven 
to eight layers of paraffin film. Using a heating block, the tube was heated at 100 C for 6 hours. 
The mixture was vortexed every 1 hour. After heating for 6 hours, the mixture was kept on 
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open bench for at least 30 minutes. Once it reached the room temperature, the mixture was 
evaporated to dryness using a vacuum evaporator. MilliQ water (4 mL) was added into the tube 
containing the dry sample, vortex mixed for 2 minutes. The mixture was then underwent 
centrifugation for 20 minutes under 3000 rpm. The supernatant was carefully taken and 
subjected to HPLC analysis. Each sample was prepared in duplicate and analysed in duplicate. 
 
2.2.5.2 Digestion using 20% trifluoroacetic acid  
Digestion of fucoidan was also performed  using 20%(v/v) TFA as described previously87. 
Fucoidan (15 mg) was weighted, transferred into a 20 mL volumetric flask. MilliQ water         
(10 mL) was added, then underwent sonication for 15 minutes or until fucoidan was completely 
dissolved. MilliQ water was then added to volume and thoroughly mixed. The solution (1 mL) 
was taken and transferred into a 15 mL centrifuge tube and was evaporated to dryness. TFA 
(20%, 3 mL) was added into the dry sample. The tube’s cap was tightly closed and sealed with 
seven to eight layers of paraffin film. Using a heating block, the tube was heated at 100 C for 
6 hours. The mixture was vortexed every 1 hour. After heating for 6 hours, the mixture was 
kept on open bench for at least 30 minutes. Once it reached the room temperature, the mixture 
was evaporated to dryness using a vacuum evaporator. MilliQ water (4 mL) was added into the 
tube containing the dry sample, vortex mixed for 2 minutes. The mixture was then underwent 
centrifugation for 20 minutes under 3000 rpm. The supernatant was carefully taken and 
subjected to HPLC analysis. Each sample was prepared in duplicate and analysed in duplicate. 
 
2.2.6 HPLC analysis 
2.2.6.1 Reversed phase chromatography with Tributylamine 
Reversed phase chromatography using a C18 column, Grace Apollo C18 5 µm (250 mm, 4.6 
mm ID) was used to resolve fucose. A security guard column (FC-2000 cartridge, Phenomenex, 
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NSW, Australia) was attached to the inlet of the column. Linear gradient of mobile phase 
consisted of 7.5 or 15 mM Tributylamine (TBA) in acetonitrile and 7.5 or 15 mM TBA in water 
with constant flow rate of 1.0 mL/minute was used. Mobile phase was filtered using 0.45 µm 
pore size nylon filter paper with and degassed using an ultra-sonic bath before use. The 
composition and linear gradient is shown in table 2.1. 
 
Table 2.1 Change in mobile phase composition over time 
Time (minute) 7.5 or 15 mM TBA in water 7.5 or 15 mM TBA in ACN 
0 98% 2% 
120 20% 80% 
 
Mobile phase was run for at least one hour to have the column fully equilibrated. A Diode array 
detector was employed to detect fucose at four different wavelength of 190 nm, 210 nm, 232 
nm, and 254 nm.  
 
2.2.6.2 Reversed phase chromatography with protamine sulphate 
Mobile phase containing protamine sulphate was used in a reversed phase mode to separate 
fucose. Stock solution of protamine (with molecular weight of approximately 5 kDa) was used 
to make mobile phase consisted of 1 µM protamine in water and 1 µM protamine in acetonitrile. 
Protamine stock solution (125 µL) was dissolved in 250 mL of MilliQ water or acetonitrile to 
make this solution. Mobile phase was also filtered using 0.45 µm pore size nylon filter paper 
with and degassed using an ultra-sonic bath before use. A Microsorb C18 column (150 mm, 4.6 
mm ID) (Varian, CA, USA) was used. A Grace C18 guard column was attached to the column’s 
inlet. A Dionex UV-Vis detector was employed to detect fucose and the wavelength of 
detection was set to 195 nm. Mobile phase was run in linear gradient mode with its change in 
concentration over time is shown in table 2.2. 
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Table 2.2 Change in mobile phase composition over time 
Time (minute) 1 µM protamine in water 1 µM protamine in ACN 
0 95% 5% 
15 50% 50% 
16 95% 5% 
20 95% 5% 
 
2.2.6.3 Reversed phase chromatography with TFA 
Mobile phase containing TFA was used in a reversed phase mode to separate fucose. TFA        
(1 mL) was dissolved in 1000 ml of Milli-Q water or acetonitrile to make a total concentration 
of 0.1% TFA.  Mobile phase was also filtered using 0.45 µm pore size nylon filter paper with 
and degassed using an ultra-sonic bath before use. A Microsorb C18 column (150 mm, 4.6 mm 
ID) (Varian, CA, USA) was used and a Grace C18 guard column was attached to its inlet. 
Mobile phase was run in a linear gradient mode with its change in concentration over time is 
shown in table 2.3. A Dionex UV-Vis detector was utilised to detect fucose in the sample and 
the wavelength of detection was set to 195 nm.  
 
Table 2.3 Changes in mobile phase composition over time 
Time (minute) 0.1% TFA in water 0.1% TFA in ACN 
0 95% 5% 
15 50% 50% 
16 95% 5% 
20 95% 5% 
 
2.2.6.4 Normal phase chromatography using an amino column (stage 1) 
Solutions containing 1 mg/mL of fucose, xylose, fructose, glucose and galactose made in 
2.2.1.1 was used. In a 15 mL centrifuge tube, a solution containing mixture of the 
monosaccharides were made with the final concentration of each monosaccharide in the 
solution was 100 µg/mL. Each monosaccharide solution (10 µL) was injected into a Shodex 
Asahipak NH2P-50 4E column (250 mm, 4.6 mm ID) (Shodex, Tokyo, Japan) with Asahipak 
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NH2P-50G 4A guard column (Shodex, Tokyo, Japan) attached to its inlet. The column 
compartment temperature was set   at 30 °C. Mobile phase, consisted of MilliQ water and ACN, 
was used in a linear gradient mode at a flow rate of 1 mL/minute. Various linear gradient 
parameters were used as shown in Table 2.4. Mobile phase was also filtered using 0.45 µm 
pore size nylon filter paper with and degassed using an ultra-sonic bath before use. The samples 
compartment temperature was set at 10 °C. 
 
Table 2.4 Changes in mobile phase composition over time 
 
 
 
 
 
 
 
 
 
 
Different method was also tried by running mobile phase in isocratic mode with composition 
of water and ACN shown in table 2.5. Other parameters; flow rate, column temperature, sample 
temperature and CAD parameters; were kept the same. 
 
 
 
 
Trial Time (minute) Water ACN 
Trial 1 0 20% 80% 6 30% 70% 
Trial 2 0 24% 76% 6 30% 70% 
Trial 3 0 24% 76% 10 30% 70% 
Trial 4 0 24% 76% 10 28% 72% 
Trial 5 0 24% 76% 12 28% 72% 
Trial 6 0 24% 76% 10 32% 68% 
Trial 7 0 24% 76% 15 32% 68% 
Trial 8 0 24% 76% 15 28% 72% 
Trial 9 0 24% 76% 15 26% 74% 
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Table 2.5 Changes in mobile phase composition over time 
 
A charged aerosol detector (CAD) was employed to detect various monosaccharides. The 
mobile phase is normally converted to small droplets due to the pressure from the nitrogen gas. 
This pressure was constantly maintained at 35.0±0.1 psi. Total gas flow on the CAD was 
observed at 1.03 when the acquisition was running while flow ratio was at 0.96 and the voltage 
was set to be at 20.6 Volt. Data acquisition and instrument control were performed using 
Chromeleon 7 Chromatography Data System.  
 
2.2.6.5 Normal phase chromatography using an amino column (stage 2) 
Normal phase chromatography with an amino column in stage 2 used a mixture of ammonium 
acetate solution and ACN as mobile phase. Other parameters were kept the same to that of the 
method in 2.2.5.4. Ammonium acetate solution was made by dissolving ammonium acetate 
crystal in MilliQ water to a certain final concentration. The pH of this solution was then 
adjusted by adding diluted acetic acid (1% v/v) until the expected pH (4.0, 4.75 and 5.0) was 
achieved. This ammonium acetate solution was then filtered through 0.45 µm pore size nylon 
filter paper and degassed with ultra-sonic bath before use. 
 
2.2.6.6 Optimisation of the method candidate 
Fucose-spiked plasma sample was prepared using a method described in 2.2.1.3. Several 
parameters of the chromatography were changed to obtain a method which give optimum 
Trial Water ACN 
Trial 1 30% 70% 
Trial 2 25% 75% 
Trial 3 20% 80% 
Trial 4 15% 85% 
Trial 5 10% 90% 
Trial 6 5% 95% 
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performance in terms of peaks separation and intensity which are depicted by several 
chromatographic parameters namely: peak intensity, resolution, asymmetry and theoretical 
plate number. These included the use of different composition of ammonium acetate and ACN, 
different pH of the ammonium acetate solution, different strength of the ammonium acetate 
and also the filter and power function value in CAD.  
 
Mobile phase containing ammonium acetate and ACN with the percentage composition of 
30:70, 25:75, 20:80, 15:85 or 10:90 was used. Ammonium acetate with the concentration of 
2.5, 5, 10, 25 or 50 mM was used. Various pH of ammonium acetate of 4.0, 4.75 or5.0 was 
also used to determine the influence of the pH to the analysis. Changes were also made to the 
filter and power function value of the charged aerosol detector to fine tune the chromatogram. 
The filter setting was set to 3, 5 or 7, while the power function value of the CAD was changed 
to 1.0, 1.5 or 2.0. 
 
2.2.7 Assay performance 
The performance of the method was validated according to Q2 (R1) guideline: Validation of 
Analytical procedure from International Conference of Harmonisation (ICH). This included 
determination of the method’s specificity, linearity, accuracy, precision, and robustness. 
 
2.2.7.1 Specificity 
Specificity of the developed method was determined by analysing four different types of 
samples: fucose standard solution in water containing 25 µg/mL of fucose, blank plasma, blank 
plasma spiked with fucose solution containing 25 µg/mL of fucose and blank plasma spiked 
with fucoidan solution containing 200 µg/mL of fucoidan.  
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2.2.7.2 Linearity 
Different concentration of fucose solutions (1-80 µg/mL) were used to determine the 
relationship between fucose concentration and CAD response. Calibration curve was made by 
plotting fucose concentration and peak area to generate equation formula and regression 
coefficient.  
 
2.2.7.3 Accuracy, precision and reproducibility 
Different solutions of fucose with low, medium and high concentration were used to determine 
the accuracy, precision and reproducibility of the developed method. Regression equation was 
used to determine the concentration of fucose based on the detected area. Intra- and inter-day 
accuracy value (n=6) for each concentration were calculated with the formula:  


 100 
where C0 is the expected concentration and C1 is the obtained concentration of the sample. 
Intra- and inter-day (5 consecutive days) precision was determined using peak areas by 
repeated analysis of each samples (n=6). Reproducibility was investigated by determining 
mean intra- and inter-day (5 consecutive days) peak retention time of each analyte (n=6). 
 
2.2.7.4 Robustness 
The robustness was investigated by repeated injection of fucose standard (n=6, 50 µg/mL) and 
slightly altering four of the chromatographic parameters; the concentration of ammonium 
acetate (4.5 or 5.5), the pH value of ammonium acetate (4, 4.75 or 5), flow rate of the mobile 
phase (0.95 to 1.05 ml/minute) and the temperature of the column (28 to 32°C). 
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2.2.7.5 Stability 
Blank plasma (n=5) were spiked with 50 µg/mL of fucose. Samples were subjected to protein 
precipitation using acetonitrile. Protein precipitate was then underwent digestion with            
20% TFA. The supernatant obtained after centrifugation was then subjected to HPLC analysis 
(Day 0) or stored at -20°C for up to a period of 31 days. The stored samples were withdrawn 
after 7, 14, 21 and 31 days and thawed at room temperature before HPLC analysis. The peak 
area of each analyte was compared to that obtained on the initial day of analysis (Day 0). 
 
2.2.7.6 Extraction recovery 
Recovery of fucoidan and fucose in plasma was investigated by comparing the concentration 
of the spiked fucose in blank plasma after precipitation using acetonitrile as described in 2.2.3.4 
to that dissolved in water. Recovery was calculated with the formula  
 

	
 100 
where Cp is the concentration of fucose in blank plasma and Cw is the concentration of fucose 
in water. 
  
2.2.8 Patients 
2.2.8.1 Recruitment 
Patients were recruited based on inclusion and exclusion criteria listed in table 2.5. Recruitment 
was performed in accordance with the National Health and Medical Research Council 
(NHMRC) National Statement on Ethical Conduct in Human Research (Commonwealth of 
Australia, 2007), the 18th World Medical Assembly (Helsinki 1964) and amendments at 
subsequent World Medical Assembly. Identification of the patients was done by the 
participating oncologist, surgeons or health care workers. Certain patients-related information 
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were recorded. These included trial code; patient’s initials and hospital number (URN); and 
completed eligibility checklist. These information were retrieved from the patient registration 
log which were created by the participating treatment centre. 
 
Table 2.6 Inclusion and exclusion criteria for patient recruitment 
Inclusion 
criteria 
1. Patients have been diagnosed to have active malignancy of either 
organ tumour or lymphoma 
2. 
Patients also were suitable candidate for active treatment for their 
malignancy with either chemotherapy or hormonal therapy which will be 
determined by their treating oncologist 
3. Patients were 18 years old or older 
4. Written informed consent have been given to all the patients prior to the 
recruitment 
5. Patients have the ability to swallow capsule 
6. 
Patients were assured to be accessible for treatment and follow-up. 
Patients randomised in the study were also available for complete 
documentation of the treatment, adverse reactions and follow up. 
7. Patients have completed 1 cycle of chemotherapy or 4 weeks of hormonal therapy 
8. Patients also had at least 2 cycles of chemotherapy or 3 weeks of hormonal therapy remaining in their planned treatment course 
Exclusion 
criteria 
1. 
Patients reluctant or unable to cease other CAM (including traditional 
Chinese medicine, other herbal, homeopathic or naturopathic 
medicine) at least week prior to trial commencement 
2. ECOG Performance status of ≥ 3 
3. Life expectancy of less than 12 weeks 
4. Inadequate haematopoietic (WBC < 3.0 x 109/L; ANC < 1.5 x 109/L, platelet < 100 x 109/dL),  or renal function (GFR < 50 mL/min) 
5. Inadequate hepatic function (either AST/ALT > 2.5 x ULN, or > 5 x ULN in case of liver metastases, or bilirubin > 1.5 x ULN) 
6. Pregnant or lactating women 
7. 
Cerebral or leptomeningeal metastases that are unstable in spite of 
appropriate therapy. Serious inter-current medical illness including (but 
not restricted to) HIV, active infection, unstable angina, severe heart 
failure, or ongoing surgical complications 
8. Major surgery within 2 weeks prior to study commencement 
9. Concurrent Radiotherapy 
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Patients were receiving Docexatel with a maximum dose of between 75 and 100 mg/m2 every 
3 weeks as a single agent or undergoing hormonal treatment using Anastrozole 1 mg daily. 
Beside the chemotherapy or hormonal treatment, the patients were also given capsule 
containing Undaria pinnatifida derived fucoidan extract manufactured by Marinova Pty Ltd. 
Each patient were given 250 mg capsule containing 187.5 mg fucoidan four times a day; thus 
total of 750 mg fucoidan were given. Capsule were self-administered orally by the patients 
after food in consecutive days for the total of three weeks. 
 
2.2.8.2 Sample collection and storage 
Blood was collected at the same time of routine blood test to avoid additional venepuncture. 
Part of this blood sample was used immediately as the standard of care. Patients’ blood was 
collected prior to and after the administration of fucoidan. Other part of the blood sample for 
the determination of fucose level was stored in a freezer under the temperature of -70 °C and 
was then used once the analytical method has been developed. 
 
2.2.8.3 Patients’ plasma sample preparation 
Patients’ plasma (500 µL) was pipetted and transferred into a 15 mL polypropylene centrifuge 
tube. Into this tube, 4 mL of acetonitrile was added. The mixture was then vortex mixed for      
1 minute and centrifuged at 3500 rpm for 20 minutes. The supernatant was carefully taken and 
discarded while the precipitate was kept intact. Into the tube containing precipitate, 20% TFA 
(3 mL) was added and then vortex mixed for 1 minute. The tube’s cap was then tightly closed 
10. Clinical evidence of current or impending bowel obstruction 
11. Documented allergy to the particular CAM 
12. Concurrent warfarin therapy 
13. Patients must not be participating in (or planning to participate in) trials 
of other pharmacological agents during their time on this study 
Exclusion 
criteria 
(continue-
d…) 
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and sealed with seven to eight layers of paraffin film. Subsequently, the tube was kept on a 
heating block and heated at 100 °C for 6 hours with vortexed mixing every 1 hour. Then, it was 
kept on open bench until it reached room temperature. A vacuum evaporator was then used to 
evaporate the solution to dryness. Milli-Q water (1 mL) was then added and vortex mixed until 
the dried sample was completely dissolved. The mixture was then subjected to centrifugation 
at 3500 rpm for 20 minutes. Finally, the supernatant was carefully taken and subjected to HPLC 
analysis using the developed and validated method. The patients’ plasma sample was prepared 
and analysed once for each sample. 
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Chapter 3 – Result and Discussion 
The availability of an analytical method as a tool to reach the goal of this study, which is to 
determine whether or not fucoidan is getting absorbed after oral administration, is vital. It has 
been mentioned earlier that the method used by Irhimeh and Tokita has, to our opinion, several 
drawbacks. Therefore, different method and approach was chosen in this study. High 
Performance Liquid Chromatography (HPLC) method was used instead of the same ELISA 
method, which was also based on the following several consideration. 
 
First, there is uncertainty on the absorption of fucoidan, whether it will be absorbed as a whole 
molecule or undergo degradation in the GIT prior to the absorption, if it is absorbed at all. 
Hence, developing an HPLC method to detect fucoidan as a whole molecule was not considered 
as a feasible approach. This was also due to the fact that fucoidan has very high molecular 
weight. Resolving such a big molecule would have been tedious and time consuming without 
a guarantee that the existing compound in the subject’s plasma sample would be the same to 
that of the analyte used in the development stage. This would have also caused difficulty in 
identification of the analyte of interest due to the variety in the structure of fucoidan.  
 
Second, fucoidan consists of considerably high percentage of fucose in its structure.  Fucose is 
a monosaccharide, the simplest form of sugar. It has exact structure, molecular weight and 
other identifiable chemical properties which are valuable in identification of a compound using 
an analytical method. Hence, detecting fucose was thought to be a more probable approach 
though it was considered as an indirect determination of fucoidan. To do this, several digestion 
methods to depolymerise fucoidan into fucose was tried. The developed chromatography 
method was also aimed to detect fucose as the analyte of interest. 
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Third, the sample used in this study was human plasma which was obtained from subjects who 
have been given oral fucoidan. Fucoidan in this plasma sample was then digested into fucose. 
Due to the fact that endogenous fucose also exist in the body, it possibly added to the 
concentration of fucose from fucoidan. Hence, the amount of endogenous fucose was taken 
into consideration. Elevating fucose concentration in plasma compared to its initial 
concentration could probably resulted from the absorbed fucoidan.  
 
Fourth, analytical method using HPLC give broad choices of approach that can be taken. 
Normal phase, reversed phase, ion-pairing and ion-exchange chromatography are some of the 
possible approach in liquid chromatography which can be tried to resolve fucose in plasma. 
These includes but not limited to utilisation of different mobile phase and its composition, 
column and also detector. Each of these chromatography methods has also been tried in this 
study with different given result. One that gave the best result in resolving fucose was taken. 
 
Fifth, fucose is a sugar which its structure lack of chromophore and this limit the choice of 
detector to be used in this study. Though it can still be detected with UV detector when the 
sample solution contain high concentration of fucose, as it has been tried in this study and will 
be shown later in this chapter, still it was not considered as the best approach for several reason: 
the detection should be set at low wavelength which give high noises, the expected fucose 
concentration in plasma was very low and by increasing the amount of plasma sample to 
increase the fucose concentration will also increase other compounds concentration from the 
plasma which will interfere fucose peak. Therefore, in this study we employed Charged 
Aerosol Detector which has the ability to detect molecule based on the charged created on the 
molecule and is proportional to the quantity of the analyte present. The requirement that the 
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analyte should be non-volatile or at least semi-volatile was fulfilled since fucose is considered 
non-volatile due to its high vapor pressure. 
 
The above mentioned consideration was regarded as guideline in the method development in 
this study and will be discussed in this chapter. This study was started with the initial trial in 
obtaining appropriate chromatography method to elute fucose standard solution in water. Once 
this had been achieved, we continued to test the method on fucose-spiked plasma to obtain 
appropriate method to analyse fucose in plasma. Subsequently, several digestion methods were 
then tried to fractionate fucoidan which was spiked into plasma. The effectivity of the digestion 
method was determined by subjecting plasma containing the digested fucoidan with the method 
developed to analyse fucose-spiked plasma. Several extraction methods were also tried to 
retrieved fucose from the digested fucoidan. Finally, once the appropriate methods to digest 
fucoidan, extract fucose from plasma and analyse fucose in plasma sample had been obtained 
and developed; those methods were then applied to analyse fucose concentration in plasma 
sample containing fucoidan. 
 
The orally administered fucoidan used in this study was extracted from brown seaweed 
Undaria pinnatifida, brand Maritech®, and was obtained from Marinova. Since this was a 
commercially marketed product, its characteristic (the amount of fucose and other 
monosaccharides, the composition of sulphate group and its purity) has been well determined. 
This well characterized fucoidan assure similarity of the orally given fucoidan to each patient. 
Hence, different figure shown by the patients, either in its investigated biological effect or its 
absorption following oral administration, can probably due to different response from each 
patient to the given fucoidan. The composition of compounds exist in the Maritech® Undaria 
pinnatifida fucoidan are listed in table 3.1. 
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Table 3.1 The characteristic of the Maritech® Undaria pinnatifida fucoidan63 
 
Components 
 
 
Percentage composition (% w/w) 
 
Fucoidan ≥75.0 
Fucose 22.0 
Galactose 21.2 
Mannose 0.9 
Glucose 0.9 
Uronic acid 4.3 
Sulphate 25.2 
 
Undaria pinnatifida derived fucoidan, as well as fucoidan extracted from different seaweeds, 
has been studied for its bioactivities such as anticancer and anticoagulant properties. These 
biological properties was investigated not only in vitro but also in vivo. The result of these 
studies, particularly those obtained through in vivo investigation, are useful as they usually 
provide information about the required dose of tested fucoidan to significantly show the 
investigated effect. Hence, by using the same Undaria pinnatifida fucoidan, a relation can be 
made between the results obtained in our study to the study investigating its bioactivities. The 
amount of fucoidan absorbed after oral administration can then be compared to the dose of 
fucoidan required to promote particular investigated bioactivities. 
 
3.1 Ion-pair reversed phase chromatography 
Reversed phase method in liquid chromatography has been extensively used for the separation 
of a wide range of pharmaceutical molecules88. While it has been mostly utilised for the 
separation of non-polar molecules, the newer types of reversed phase columns have the ability 
to resolve polar compounds as well88. With increasing purity of available stationary phases, the 
reversed phase columns are now not only used for acidic molecules but also utilised for basic 
compounds88-90. Moreover, keeping the basic principle of reversed phase chromatography 
which uses non-polar column; tweaking around the method by, for example, adding ionic 
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molecule to the mobile phase had created the new term of ion-pairing chromatography with 
which ionic molecules are mostly resolved through liquid chromatography. 
 
Several studies have successfully resolved various types of carbohydrate molecules (e.g. 
heparin and heparan sulphate) using an ion-pairing reversed phase chromatography91-93. 
Therefore, we also tried the reversed-phase chromatography in the early stage of this study. 
Fucose, as other sugars, is a polar compound, making it difficult to retain and resolve on a C18 
column in the absence of an ion pairing reagent. Therefore, two different types of ion pairing 
reagents were investigated to determine their ion pair capacity and, hence, the effect on 
chromatographic separation.  
 
3.1.1 Effect of the ion pair reagents 
The effect of TBA on the separation of fucose was investigated in the concentration range of 
7.5 to 15 mM. The mobile phase was composed of TBA (7.5 mM) in water (mobile phase A) 
and TBA (7.5 mM) in acetonitrile (ACN) (mobile phase B). It was attempted to determine the 
optimal concentration of ACN for 7.5 mM TBA by steadily increasing the concentration of 
ACN from 2 to 20% over a period of 120 minutes.   However, with this approach, fucose did 
not retain onto the column and was eluted at approximately 2.5 minutes as shown in figure 3.1. 
At this point, two reasons were thought to be responsible for early elution of fucose: 1) in ion 
pair reversed phase chromatography, an analyte (e.g. fucose) interacts with the oppositely 
charged ion pair (e.g. TBA) adsorbed onto the hydrophobic surface of the column and remains 
there until the concentration of the organic modifier (in this case ACN) is sufficient enough to 
elute the analyte. Therefore, the initial concentration of ACN (2%) was considered too high 
and therefore it did not allow fucose to retain onto the column; 2) the resolving power of           
7.5 mM TBA was not sufficient enough that would allow its efficient interaction with fucose. 
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Therefore, the available approach was to further decrease the initial concentration of ACN 
and/or to increase the concentration of TBA. Hence, the concentration of ACN (containing      
15 mM TBA) was steadily increased from 0.5 to 10% over a period of 120 minutes. The 
retention time of fucose did not change despite altering the concentration of ACN to form a 
shallow gradient. Then the concentration of TBA was increased from 7.5 to 15 mM with the 
gradient of ACN from 0.5 to 10% over 120 minutes. Increased in the concentration of TBA 
also did not influence the retention time of fucose.  
 
 
Figure 3.1 RPIP-HPLC separation of fucose. Experimental conditions: Grace Apollo C18 (250_4.6 
mm), 5 µm; eluent containing 15 mM TBA in water and ACN; detection wavelength 190, 210, 235 and 
254 nm with diode array detector, flow rate 1 mL/minute, injection volume 10 µL.  
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Figure 3.2 RPIP-HPLC separation of fucose solution containing 1.25, 2.5 and 5 mg/mL of fucose. 
Experimental conditions: Grace Apollo C18 (250_4.6 mm), 5 µm; eluent containing 15 mM TBA in 
water and ACN; detection wavelength 190 nm with diode array detector, flow rate 1 mL/minute, 
injection volume 10 µL. 
 
 
Figure 3.3 RPIP-HPLC separation of blank (MilliQ water) and fucose solution containing 0.5 and        
1 mg/mL of fucose. Experimental conditions: Grace Apollo C18 (250_4.6 mm), 5 µm; eluent 
containing 0.1% TFA  in water and ACN; detection wavelength 190 nm with diode array detector, flow 
rate 1 mL/minute, injection volume 10 µL. 
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Four different UV wavelengths (190, 220, 235, and 254 nm) were used to detect fucose when 
above mentioned approach was taken.  While fucose was detected at 190 nm, no peak was 
observed on other selected wavelengths (Figure 3.1). Therefore, the separation of fucose in the 
presence of another type of ion-pairing agent was observed at 190 nm.  
 
The effect of protamine sulphate (1 µM) on the separation of fucose was also investigated. 
Protamine is a highly positively charged polypeptide which is mainly composed of the amino 
acid arginine94. Therefore, the column was first equilibrated with 1 µM of protamine sulphate 
to allow its adsorption onto the column. The linear gradient of ACN was changed from 5% to 
50% over a period of 15 minutes. However, with this approach fucose did not retain on to the 
column and eluted at approximately 2 minutes. 
 
The separation of carbohydrates using an ion-pairing reagents (such as TBA, tetra butyl 
ammonium hydroxide) has been reported before95. The analyte analysed in the previous studies 
were obtained through either chemical or enzymatic digestion of large molecules such as 
heparin and heparan sulphate. After digestion process, the obtained sugar molecules (often 
known to as oligosaccharides) had high negative charge attributed to the presence of sulphate 
groups. For example, total bonded sulphate in a low molecular weight heparin solution after 
acid hydrolysis is reported to be approximately 39% (w/w)96. These highly negatively charged 
molecules were thought to interact with the positively charged TBA or protamine sulphate 
resulting in their retention when a reversed phase C18 column was employed. Unlike 
oligosaccharides, fucose (a monosaccharide) does not possess a high net negative charge. 
Therefore, the ionic interaction between fucose and TBA or protamine sulphate was not strong 
enough for fucose to retain onto the column even when the initial concentration of organic 
modifier was as low as 0.5%.  
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One possible approach to overcome the above mentioned problem was the use of sulphated 
fucose. The presence of sulphate groups could increase the interaction between fucose and ion 
pairing reagent and hence delay the elution of fucose. However, the goal of the study was to 
investigate the concentration of fucose before and after oral administration of commercially 
available fucoidan. For this purpose, chemical digestion of patients’ plasma samples was 
required to facilitate complete breakdown of fucoidan into fucose. The digestion process results 
in a complete loss of bonded sulphate groups. Therefore, it was considered crucial to use non-
sulphated fucose during the development phase of an analytical method.   
 
3.2 Normal phase chromatography 
In normal phase chromatography, the stationary phase of a column is considerably more polar 
than the mobile phase used for the separation of an analyte. This feature of a normal phase 
column provides an advantage over reversed phase column when used for the analysis of polar 
compounds such as monosaccharides and oligosaccharides. In some cases, however, the 
utilisation of ion-pairing reagent will also improve the ability of reversed-phase 
chromatography in the analysis of polar compounds. The polar characteristic of the column’s 
stationary phase in a normal phase chromatography improves retention on such polar 
molecules. A polar analyte will easily be attracted to column’s stationary phase with similar 
polarity. The strength of mobile phase in terms of its polarity will then play a role in the 
separation of molecules in a sample when subjected to analysis with HPLC. In regards to the 
analysis of monosaccharides, some columns are, in fact, specially designed for carbohydrate 
or particularly monosaccharides analysis. One such type of column is Shodex Asahipak NH2P-
50. This column is also classified as a HILIC (hydrophilic interaction liquid chromatography) 
column97. It contains amino-bonded silica as the stationary phase. The mobile phases used with 
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amino-bonded silica columns are usually similar to that of reversed phase chromatography. 
This type of column not only allows to analyse chemically polar compounds but also those 
with a net charge in their structure98.  
 
We initially utilised this column for the separation of fucose using the method suggested by its 
manufacturer. The mobile phase was consisted of 25% water and 75% ACN. Mobile phase was 
run in isocratic mode at the flow rate of 0.5 mL/minute. Column temperature was set to 30 °C. 
Sample was auto-injected and was kept under 10 °C in an auto-sampler compartment. The type 
of detector was changed from Ultraviolet (UV) detector to Charged Aerosol Detector (CAD). 
The CAD parameters were set as: Data Collection Rate=100, Nebuliser Temperature=ambient 
temperature, Power Function=1.0, Filter Value=3.0.  
 
The utilised detector was changed due to the fact that UV detector has limitation in detecting 
compounds lack UV chromophore, such as carbohydrates. The UV detector used in the current 
study was still able to detect fucose. However, we needed to use high concentration of fucose 
(5 mg/mL) as it is shown in Figure 3.4. However, the UV intensity which was depicted by the 
height of the chromatographic fucose was quite low compared to CAD intensity. The UV 
detection of an analyte depends on the wavelength selection. Depending on the UV 
chromophore of an analyte, different wavelengths can give different intensity. The maximum 
peak intensity can be obtained at a particular wavelength depending on the type of analyte. We 
tried several wavelengths and found out that the maximum detection for fucose was at 190 nm. 
At this wavelength, noise from mobile phase was high and therefore it hampered the detection. 
The detection of fucose using UV detector was difficult when the concentration of fucose was 
lower than 5 mg/mL. On the other hand, CAD offers universal detection. This means the 
detection of an analyte depends on the mass as well as the structure of the analyte of interest. 
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It detects molecules which have been previously charged and the detector’s signal intensity 
was related to the mass of analyte flowing through the detector and not to its UV chromophore. 
 
 
Figure 3.4 Normal phase-HPLC separation of fucose solution containing 5 mg/mL of fucose. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (25:75); detection using CAD and diode array detector at wavelength 190 nm, flow rate       
1 mL/minute, injection volume 10 µL. 
 
 
Figure 3.5 Normal phase-HPLC separation of fucose solution containing 5 mg/mL of fucose. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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Figure 3.5 shows chromatogram of fucose solution eluted with the above mentioned 
chromatography parameters. It can be seen that fucose was eluted at 7.5 minutes. This retention 
time of fucose was considered suitable and therefore we decided to use this column. However, 
considering the final sample of this study was human plasma which contain endogenous 
monosaccharides such as glucose, fucose, fructose, xylose and some others; possible 
interference between fucose and these monosaccharides could occur. Hence, further adjustment 
to some of the chromatography parameters to obtain the appropriate method was needed. This 
also to at least help reduce the possibility of the endogenous monosaccharides from interfering 
fucose peak when the analysis of plasma sample was performed. To do this, mixture of 
monosaccharides was prepared as described in method 2.2.1.1. Solution containing 5 mg/mL 
of each of these monosaccharides were also prepared. These samples were then subjected to 
HPLC and were resolved with the previously developed method. 
 
Solution containing each of monosaccharide was injected separately and chromatogram was 
recorded. Figure 3.6, 3.7, 3.8, 3.9, and 3.10 are chromatograms showing peak of fucose, xylose, 
fructose, glucose and galactose, respectively.  
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Figure 3.6 Normal phase-HPLC separation of fucose solution containing 5 mg/mL of fucose. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
Figure 3.7 Normal phase-HPLC separation of solution containing xylose. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN (25:75); 
detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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Figure 3.8 Normal phase-HPLC separation of solution containing fructose. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN (25:75); 
detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
Figure 3.9 Normal phase-HPLC separation of solution containing glucose. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN (25:75); 
detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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Figure 3.10 Normal phase-HPLC separation of solution containing galactose. Experimental 
conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN 
(25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
Figure 3.11 Normal phase-HPLC separation of solution containing mixture of monosaccharides. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
Figure 3.11 shows the chromatogram of solution containing a mixture of monosaccharides 
(without glucose) eluted with mobile phase containing 25% water and 75% ACN. The retention 
time of each monosaccharide was similar to when each of them was analysed separately. 
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Fucose was eluted first at 7.550 minutes followed by xylose at 9.114 minutes, fructose at 9.747 
minutes and galactose at 11.966 minutes. The resolution between fucose and xylose peak, the 
closest eluted monosaccharide to fucose, was 3.22 which suggested that both monosaccharides 
were separated nicely. The intense noise was observed when the composition of water in the 
mobile phase was increased from 20% to 25%. However, this did not occur all the time. We 
thought, the higher noise was caused by temporary disruption to the CAD nozzle in producing 
uniform droplets of mobile phase. We then adjusted the mobile phase composition to find out 
its effect to the monosaccharides separation. Increasing water portion by 3% to 28%, which 
also changed ACN composition accordingly to make the total composition of 100%, eluted all 
the monosaccharides faster without changing the order of elution as shown in Figure 3.12. This 
also increased the peak height of all monosaccharides which also means increasing detection 
intensity. At 30% of water content in mobile phase, peak height of all monosaccharides was 
even further increased (Figure 3.13).  
 
The expected goal, by modifying the mobile phase composition, was to obtain a method which 
gives higher peak intensity from the same amount or concentration of analyte. Such method 
can possibly offer lower limit of quantification (LOQ) or at least limit of detection (LOD). 
Unfortunately, the increasing peak height, as a result of the increasing water composition in 
the mobile phase, did not produce higher peaks resolution between monosaccharides. The 
resolution between fucose and xylose decreased from 3.22 to 1.75 by 5% increase of water 
content in mobile phase. This value was above 1.5, the considered as minimum resolution, 
which suggested the two peaks were still well separated to accurately measure the peak area. 
However, xylose and fructose were eluted at almost the same time and their peak overlaid to 
one another. Therefore, we then used different mobile phase composition to obtain better 
separation between these monosaccharides. 
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Figure 3.12 Normal phase-HPLC separation of solution containing mixture of monosaccharides. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (28:72); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
Figure 3.13 Normal phase-HPLC separation of solution containing mixture of monosaccharides. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (30:70); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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in mobile phase from 20% to 30% in 6 minutes (Trial 1), with the flow rate of 1.0 mL/minute, 
eluted fucose at 7.8 minutes. Xylose and fructose were eluted afterwards and were still 
interfering with each another (Figure 3.13). Linearly changed the composition water from 24% 
to 30% in 6 minutes (in Trial 2) or 10 minutes (in Trial 3) provided no significant difference to 
that of Trial 1. Similarly, all attempts in Trial 4 to Trial 9 did not produce the expected 
separation of monosaccharaides. Running mobile phase in gradient mode also created slope in 
the chromatogram, which sometimes created difficulty in area integration. More time was also 
needed to re-equilibrate the column. Thus, in the next attempt we decreased the composition 
of water and run the elution in isocratic mode. 
 
 
Figure 3.14 Normal phase-HPLC separation of solution containing mixture of monosaccharides. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (water was linearly changed from 20% to 30%); detection with CAD, flow rate 1 mL/minute, 
injection volume 10 µL. 
 
Mobile phase consisted of 20% water and 80% ACN was eluted the monosaccharides mixture 
and was run in isocratic mode at the flow rate of 1 mL/minute. Other parameters were kept the 
same. It appeared that, compared to the previous results, the monosaccharides were well 
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resolved, particularly those between xylose and fructose (Figure 3.15). Fucose retention time 
was not significantly changed, at around 7.5 minutes which was considerably appropriate 
elution time for plasma analysis. This method was thought to be a suitable method to be used 
for preliminary test on fucose-spiked plasma and will subsequently called as the method 
candidate in this chapter. This preliminary test was intended to determine the suitability of the 
method when it is used to detect fucose in plasma, prior to investigating its application using 
patients’ plasma samples. Relying on the results obtained through analysis of fucose standard 
solution was not enough due to the presence of various compounds in plasma. These 
compounds could potentially interfere fucose which could then hamper the detection of fucose. 
Therefore, adjustment to the method, when needed, was performed until a suitable method was 
obtained. 
 
 
Figure 3.15 Normal phase-HPLC separation of solution containing mixture of monosaccharides. 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
Another important thing to consider in the analysis of plasma samples using HPLC was the 
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not removed properly, can also decrease the column’s life time and possibly block HPLC 
compartment such as HPLC flow lines or UV flow cells. On CAD, plasma protein can block 
the nozzle leads to increasing pressure and disturb conversion of mobile phase into droplets. 
Hence, several protein precipitation (PPT) methods were tried and its efficacy in removing 
plasma proteins was tested with the HPLC method suitable for preliminary test. Recovery test 
of the utilised PPT method was also investigated. This to ensure that the method capable of not 
only in removing plasma protein but also in preserving fucose in the plasma sample or 
retrieving fucose from plasma, which depends on the type of the method utilised. 
 
3.3 Plasma protein precipitation Methods 
3.3.1 Plasma Protein Precipitation using Ammonium sulphate saturated solution 
We used ammonium sulphate saturated solution (ASSS) to precipitate plasma proteins and the 
method is described under 2.2.3.1 Precipitation using ammonium sulphate. Ammonium 
sulphate saturated solution has been used to precipitate plasma protein in several studies99-101. 
We investigated the optimum volume needed to precipitate plasma protein by mixing different 
volumes of ASSS with one part volume of the blank plasma (Table 3.2). 
 
Table 3.2 Precipitation of blank plasma proteins using different volumes of ammonium sulphate 
saturated solution (ASSS). 
Plasma (part volume) ASSS (part volume) Result 
1 1 Clear solution 
1 2 Clear solution 
1 3 Clear solution 
1 4 Clear solution 
1 5 Clear solution 
 
We found out that 1 part or equal volume of ASSS was sufficient to precipitate proteins evident 
by the appearance of clear final solution at the top after precipitation procedure was applied. 
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Plasma proteins were observed to be precipitated at the bottom of the test tube. Up to this stage, 
this method was then tested to precipitate plasma proteins. The supernatant obtained after 
precipitation using ASSS was subjected to HPLC analysis using the method candidate. The 
first injection gave broad peaks started from 2 to 8 minutes (Figure 3.16). Since the retention 
time of fucose using this method was at around 7.5 minutes, this suggested that the endogenous 
substances would interfere with the elution of fucose. 
 
 
Figure 3.16 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using an equal volume of ammonium sulphate saturated solution (ASSS). Experimental 
conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN 
(20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
We then injected ASSS solution containing equal amount of ASSS to that present in the plasma 
sample to investigate the source of those big peaks eluted from approximately 2 minutes to 7.5 
minutes. It can be seen from Figure 3.17, that though quite broad peaks were obtained, those 
were smaller compared to the chromatogram of the supernatant obtained after precipitation 
using ASSS as described above. The chromatogram showed peaks started from 2.5 to around 
5 minutes which was far enough from possible eluted fucose peak. Spikes were observed on 
the chromatogram. We thought that the observed spikes were caused by dirty nebuliser nozzle 
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in CAD due to the injection of plasma. Thus, mobile phase was pumped for approximately an 
hour until no spikes were observed and straight baseline was obtained. 
 
 
Figure 3.17 Normal phase-HPLC separation of ammonium sulphate saturated solution (ASSS). 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
The supernatant taken from the same sample was re-injected to confirm whether the early 
eluted broad peaks come from the plasma or due to the existence of ASSS. We initially thought 
to make necessary adjustment to the method to improve separation if the result was repeatable. 
However, broader peaks were again observed. Unlike in the first injection, this time the 
compounds were eluted from 2 to 14 minutes (Figure 3.18). Another injection of the same 
sample also showed similar results. We at this stage thought that some portion of the sample 
was retained in the column and this part of the sample was eluted in the next sample run. This 
was probably caused by poor solubility of the retained compounds in the mobile phase or they 
were strongly attached to the stationary phase in the column, hence mobile phase was not strong 
enough to elute all the compounds. Another possible cause was the incompatibility of 
ammonium sulphate as the precipitating agent with the column. Despite the clear appearance 
 75 
 
observed following precipitation with ASSS, there was probably some portion of this 
precipitating agent dissolved in the supernatant. This can be seen by noisy and inconsistent 
baseline observed in the chromatogram above (Figure 3.17). 
 
  
Figure 3.18 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using an equal volume of ammonium sulphate saturated solution (repeated injection). 
Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water 
and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
To investigate the cause of this problem, a solubility test was performed. This test was 
conducted by mixing several solutions: fucose solution in water (FS), ammonium sulphate 
saturated solution (ASSS), water (W) and acetonitrile (ACN)] with each other and the results 
are shown in Table 3.3. Since the mobile phase consisted of mostly ACN, poor solubility in 
ACN could have prevented either fucose or ammonium sulphate from ASSS to be completely 
eluted from the column. This with regards to the possibility that ASSS could be present in the 
supernatant. Hence, the aim of this test was to determine the solubility of the compounds 
present in the sample with the mobile phase and the miscibility of one another. 
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Table 3.3 Solubility test involving fucose solution, mobile phase and ammonium sulphate saturated 
solution 
Test Mixed 
solution Result Appearance 
Test 1 FS + ASSS Immiscible Hazy solution was obtained 
Test 2 FS + ACN Miscible Clear final solution 
Test 3 W + ASSS + ACN Immiscible 
Three layers of immiscible solutions 
were obtained 
Test 4 FS + W + ACN Miscible Clear final solution 
Test 5 FS + ASSS + ACN Immiscible 
Four layers of immiscible solutions were 
obtained 
 
It can be seen from the table that whenever ASSS was mixed with either fucose solution or 
ACN, immiscible solution was obtained. On the other hand, a mixture containing fucose 
solution, water and ACN showed miscible solution. This suggested that ASSS was not miscible 
with the mobile phase utilised in the method. This suggested that ASSS could potentially 
precipitated in either water or ACN or both at some extent. Hence, it would have caused 
retention of ammonium sulphate and it remained in the column for sometimes.  Because of 
this, we concluded that ASSS was not a suitable agent to precipitate plasma protein if the same 
chromatographic method was used. Therefore, another type of precipitating agent was tested.  
 
3.3.2 Plasma protein precipitation using 95% ethanol 
Ethanol, beside ammonium sulphate, had been reported to be useful for precipitation of plasma 
proteins. The precipitation of plasma proteins was carried out as described under 2.2.3.2 
Precipitation using ethanol. We tried two different approaches of plasma protein precipitation 
using ethanol. The first method was a modification of a method previously described by 
Subhash et al. 83. The second one was a replication of what was described by Jianguo et al.84.   
 
In the first method, we initially determined the optimum volume of 95% ethanol needed to 
precipitate plasma proteins (Table 3.4). 
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Table 3.4 Blank plasma protein precipitation using different volume of 95% ethanol 
Test 
Step 1 Step 2 
Result Plasma 95% Ethanol Supernatant 
95% 
Ethanol 
Solution A 100 µL 300 µL 200 µL 200 µL Hazy solution 
Solution B 100 µL 350 µL 200 µL 200 µL Slight-hazy solution 
Solution C 100 µL 400 µL 200 µL 200 µL Clear solution 
 
In the first step, blank plasma (100 µL) was taken and then 300 (solution A), 350 (solution B), 
or 400 µL (solution C) of 95% ethanol was added. In the second step, the supernatant (200 µL) 
was taken and then an equal volume of 95% of ethanol was added. A hazy or slightly hazy 
solution was obtained when supernatant was taken from solution A or solution B. However, a 
clear solution was obtained after addition of 400 µL of 95% ethanol to the supernatant taken 
from solution C. Therefore, it was considered that four times volume of 95% ethanol was 
sufficient to completely precipitate proteins present in plasma samples. This suggested that the 
addition of 300 µL and 350 µL of 95% ethanol was not enough to completely precipitate protein 
from 100 µL plasma. Hence, four times volume of 95% ethanol was considered as the optimum 
volume to precipitate plasma protein and was tried in this study. The supernatant obtained from 
this method was then subjected to the HPLC analysis using the method candidate described 
above (sub chapter 3.2).  
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Figure 3.19 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using four times volume of 95% ethanol. Experimental conditions: Shodex Asahipak NH2P-50 
4E (250_4.6 mm), 5 µm; eluent containing water and ACN (20:80); detection with CAD, flow rate        
1 mL/minute, injection volume 10 µL. 
 
Figure 3.19 shows the chromatogram of supernatant obtained after precipitation of plasma 
proteins using four times volume of 95% ethanol. It is apparent from the chromatogram that 
endogenous compounds from blank plasma were still observed in the supernatant and could 
have disturbed elution of fucose. Similar to that of the chromatogram obtained after 
precipitation using ASSS, continuously eluted endogenous compounds were observed from      
2 minutes to around 10 minutes. Continuously eluted compounds were also detected in the 
supernatant following precipitation using cold ethanol (Figure 3.20). Two peaks from unknown 
compounds were detected at around the expected retention time of fucose. This will similarly 
hinder the detection of fucose in the injected supernatant. Hence, we decided to again use 
different precipitating agent. This time we used 80% ACN. 
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Figure 3.20 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using cold ethanol. Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm),   
5 µm; eluent containing water and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection 
volume 10 µL.  
 
3.3.3 Plasma protein precipitation using 80% ACN 
We used 80% ACN to precipitate plasma proteins. ACN has been proven to be effective in 
removing plasma proteins as a part of sample preparation for analysis with either liquid 
chromatography or mass spectrometry. However, due to poor solubility of fucose in ACN, we 
added water to make solution similar to that of the mobile phase which contain 80% ACN and 
20% water. We did simple solubility test by dissolving 5 mg of fucose in 6 mL of 80% ACN 
and obtained completely soluble fucose solution. Hence, this solution contained approximately 
0.8 mg/mL fucose which was considerably higher than the estimated fucose concentration in 
plasma. High concentration of ACN was expected to precipitate plasma protein while keeping 
the ability to dissolve fucose. 
 
Plasma protein precipitation using 80% ACN was performed as described under method 2.2.3.3 
Precipitation using 80% ACN. Figure 3.21 shows chromatogram of the supernatant obtained 
after precipitation using 80% ACN. Similar to the chromatogram of supernatant obtained after 
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precipitation using ASSS and ethanol, endogenous compounds were shown to be continuously 
eluted starting from 2 to around 9 minutes. Hence, both elution and the detection of fucose 
could potentially be interfered by endogenous compounds from the blank plasma. 
 
 
Figure 3.21 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using 80% ACN. Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm),       
5 µm; eluent containing water and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection 
volume 10 µL. 
 
At this point, we had used three different types of precipitating agents. However, they seemed 
to be not suitable in improving the separation of blank plasma containing fucose using the 
method candidate. Hence, the reason for this poor chromatographic separation was probably 
due the type of chromatographic method used in this study and not the utilised precipitation 
method. All the precipitating agents used in the current study have been shown to be effective 
in removing plasma proteins102-104. For instance, a study conducted by Rajasekhar et al. 
suggested that the ACN was effective in precipitating plasma proteins104. However, they used 
ODS (Octa Decyl Sylane) column which is a non-polar column instead of a polar column which 
was used in this study. They also used a mixture of ACN and ammonium acetate buffer solution 
to elute the sample. Disregarding the type of analyte of interest, different types of columns and 
 81 
 
eluents have probably given different response to the ACN-extracted plasma sample, hence 
different results were obtained. Because of this, we focused on modifying the chromatographic 
parameters to obtain a suitable method capable of separating fucose from other endogenous 
compounds present in plasma. Since we preferred to keep using the Asahipak NH2P-50 column 
in this study, the first attempt was targeted on modifying the mobile phase. This included 
changing the currently used mobile phase composition, type of elution (whether isocratic or 
gradient), and finally changed the type of mobile phase and its composition. Precipitation 
method using 80% ACN was kept, not only because it can precipitate plasma proteins but also 
was similar to the utilised mobile phase in the method candidate. 
 
We modified the mobile phase to have several different compositions of water and ACN to see 
the influence of this modification to the elution of fucose-spiked blank plasma. Mobile phase 
consisted of water and ACN of 30%:70%, 25%:75%, 15%:85%, 10%:90% or 5%:95% were 
tested. Mobile phase composition was changed through the option available in the instrument 
controller and was mixed using low pressure gradient mixing mode. We also temporarily used 
UV detector instead of CAD since there were no significant detection differences between UV 
and CAD response when a solution containing high concentration of fucose (1 mg/mL) was 
used. This way we focused on obtaining a method which can appropriately separate fucose and 
other components present in plasma without necessarily utilising Nitrogen gas as if CAD was 
used. Solution containing 1 mg/mL of fucose in water was made and 10 µL of this solution 
was injected to determine retention time of fucose in the tested mobile phase composition prior 
to analysing fucose-spiked blank plasma. This way, possible interference from the endogenous 
compounds in plasma on fucose could be determined. Then, further adjustment to mobile phase 
composition could necessarily be applied until no interfering compounds were observed. 
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The result of this test showed that mobile phase consisted higher composition of water, with 
the respective composition of water and ACN (25:75), eluted endogenous compounds from 
plasma with shorter elution time compared to when mobile phase consisted of Water:ACN 
(20:80) was utilised. Figures 3.22 and 3.23 show the chromatograms of fucose and plasma 
supernatant (obtained after precipitation of blank plasma with 80% ACN) respectively. The 
retention time of fucose was observed to be 5.5 minutes and multiple peaks were eluted (from 
2 to 10 minutes) when plasma supernatant was analysed. The multiple peaks were also 
observed at around fucose retention time when water composition in mobile phase was linearly 
changed from 25% to 20% in 20 minutes as shown in Figure 3.24. 
 
 
 
Figure 3.22 Normal phase-HPLC separation of solution containing 1 mg/mL of fucose. Experimental 
conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing water and ACN 
(25:75); detection wavelength 190 nm with diode array detector, flow rate 1 mL/minute, injection 
volume 10 µL. 
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Figure 3.23 Normal phase-HPLC separation of supernatant obtained after precipitation of blank plasma 
using 80% ACN. Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent 
containing water and ACN (20:80); detection wavelength 190 nm with diode array detector, flow rate    
1 mL/minute, injection volume 10 µL. 
 
 
 
Figure 3.24 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using 80% ACN. Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm),       
5 µm; eluent containing water and ACN (water was linearly changed from 25% to 20%); detection 
wavelength 190 nm with diode array detector, flow rate 1 mL/minute, injection volume 10 µL. 
 
On the other hand, decreasing the composition of water in mobile phase to 15% increased 
elution time of all endogenous compounds. Even longer time was needed to elute these 
compounds when mobile phase containing 10% or 5% of water was used. 
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At this point, we concluded that mobile phase consisted of only water and ACN would not be 
able to resolve fucose and other substances present in plasma from each other with the currently 
used column. We decided to modify the mobile phase and looked upon the use of salt buffer 
for this type of column. Mobile phase consisted of water and ACN resolved the injected sample 
mainly based on polarity. Asahipak NH2P-50 4E is an amino column and its stationary phase 
composed of polyamine attached to hydrophilic polymer gel. The availability of amine group 
brings polar property to the column which is one of the reasons it can retain polar compounds 
such as monosaccharides. Elution of monosaccharides occur in the order of increasing polarity. 
Hence, compounds with more polarity retains for a longer period of time than those with less 
polarity. Amine groups also creates an alkaline environment in the column which offers 
additional advantages in the analysis of monosaccharides with anomeric carbon atom. It 
prevents the separation of monosaccharide anomers which can cause split peak when analysis 
is performed at room temperature105. 
 
On the other hand, salt buffer in mobile phase can change the chemical properties of the 
column’s stationary phase. Hence, the separation of compounds occur not only due to polarity 
but also because of the interaction between mobile phase, sample and stationary phase98. 
Introduction of mobile phase containing buffer, particularly ammonium acetate, alters the 
separation characteristic of the column. Amine groups can also be considered as an ion 
exchange resin, more specifically anion exchange resin. Composition of ammonium acetate in 
mobile phase and its pH determines the ratio of non-protonated/protonated amine group in the 
stationary phase. Ammonium acetate solution with high pH gives  a greater ratio of non-
protonated/protonated amine, uses low elution volume and produces high and sharp peaks 
when used with Shodex Asahipak column 98,105,106. 
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The utilisation of ammonium acetate in this study was in line with several considerations. First, 
ammonium acetate has been commonly used as buffer additives in mobile phase. Second, as 
mentioned earlier, ammonium acetate can alter the ratio of non-protonated/protonated amine 
groups present on the stationary phase of Shodex Asahipak column. This would then change 
the separation characteristic of the column. Third, buffering capacity of ammonium acetate 
solution can be obtained when the pH is adjusted to 3.8-5.8. Maximum buffering capacity is at 
pH 4.75. This pH value is considered appropriate when the CAD is employed as a detector. 
The CAD is compatible when the pH of mobile phase is below 7.5. Four, ammonium acetate 
easily vaporises which is one of the requirements for buffer additives when CAD is utilised. 
Therefore, based on these criteria, we decided to use ammonium acetate as buffer additive in 
mobile phase. 
 
The addition of ammonium acetate buffer to the mobile phase significantly improved 
separation of fucose and other compounds in the plasma compared to when the mobile phase 
consisted only water and acetonitrile. Nonetheless, it appeared that acidic environment in the 
column affected the separation of some of the components presents in plasma but not fucose. 
There was no major change in the retention time of fucose when ammonium acetate was 
introduced into mobile phase. In contrast, some compounds were observed to be eluted faster 
than other. 
 
The option to use salt buffer other than ammonium acetate was limited. There are other 
buffering agents recommended by the manufacturer of the utilised CAD detector: TFA, formic 
acid and ammonium formate. However, we preferred to use ammonium acetate among others 
since its maximum buffering capacity can be obtained at a bit higher pH value; pH 4.76 
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compared to 0.3 for TFA and 3.75 for formic acid and ammonium formate. Adjusting mobile 
phase to a very low pH value as a result of the utilisation of TFA, formic acid or ammonium 
formate could drastically change the initial basic environment of the column. This could 
probably decrease the lifetime of the column, while the expected figure of separation obtained 
by the use of these buffer agents would not significantly improved than that of ammonium 
acetate. 
 
The option to use phosphate buffer was not also possible to be taken. This is because phosphate 
is non-volatile and hence not compatible with CAD. The solubility of phosphate buffer in ACN 
is also considerably low. Hence, it would have limited the option to alter the composition of 
mobile phase or to adjust the strength of phosphate buffer since the mobile phase was also 
composed of ACN. Therefore, based on these considerations, we decided to use ammonium 
acetate as buffer additive in mobile phase. 
 
3.4 Optimisation of mobile phase: the utilisation of ammonium acetate 
We initially used a 5 mM ammonium acetate solution. The pH of ammonium acetate solution 
was adjusted to 4.75 with diluted acetic acid. This solution was filtered using a 0.45 µm pore 
size filter paper and was degassed before use. The mobile phase was composed of 20% of           
5 mM ammonium acetate solution (pH 4.75) and 80% of ACN. Other chromatographic 
parameters were kept the same to the method candidate described in sub chapter 3.2. The 
column was equilibrated by flushing mobile phase for 30 minutes. We used fucose-spiked 
blank plasma with quite high concentration of fucose (1 mg/mL) in order to easily observe 
fucose peak and the quality of separation from other interferences. 
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Initially, fucose solution (500 µL) was added to the blank plasma (500 µL). The resulting 
solution was then precipitated using 80% ACN as described above (sub chapter 3.3.3). The 
supernatant was taken and analysed using HPLC. The chromatogram obtained after injection 
of plasma containing fucose is shown in Figure 3.25. It can be seen from the chromatogram 
that the utilisation of ammonium acetate buffer solution in mobile phase significantly improve 
the separation between fucose and endogenous compounds from blank plasma. Fucose was 
eluted at around 7.5 minutes. However, it was co-eluted with other unknown compounds 
present in plasma.  The co-eluted fucose peak was confirmed by comparing the retention time 
of co-eluted peak with the retention time of fucose (Figure 3.26). This showed that the 
separation of fucose from other compounds was improved with a mobile phase containing 
ammonium acetate buffer compared to when mobile phase consisted of only water and ACN 
was utilised. Endogenous compounds which were previously observed to be eluted from 2 to 
12 minutes (figure 3.23), this time were eluted faster to until around 7 minutes (ended slightly 
before fucose which we thought was observed at around 7.5 minutes). 
 
 
Figure 3.25 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using 80% ACN. Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm),       
5 µm; eluent containing 5 mM Ammonium acetate pH 4.75 and ACN (20:80); detection with CAD, flow 
rate 1 mL/minute, injection volume 10 µL. 
Fucose 
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Figure 3.26 Normal phase-HPLC separation of solution containing fucose. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 
4.75 and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
We again let the mobile phase run through the column for another 1 hour to give more time for 
the column to be fully conditioned with the mobile phase before reinjecting the same sample. 
Figure 3.27 shows the chromatogram of the same supernatant sample which was reinjected 
after another 1 hour of column conditioning. It can be seen from the chromatogram that, 
compared to figure 3.25, fucose was clearly separated from other components in the sample. 
The resolution between fucose and the earlier eluted compounds was also significantly 
increased. This suggested that the utilisation of ammonium acetate in mobile phase has 
improved separation between fucose and other components present in plasma. Hence, we kept 
this mobile phase and made further adjustment to its composition and other chromatographic 
parameters to obtain the most suitable chromatographic system. Several parameters were 
adjusted which include adjustment of mobile phase composition, the pH of ammonium acetate 
solution and the strength of ammonium acetate solution. To improve the detection of fucose, 
two parameters in CAD were also modified, namely power function (PF) and filter value (FV). 
 
Fucose 
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Figure 3.27 Normal phase-HPLC separation of supernatant obtained after precipitation of blank 
plasma using 80% ACN (re-injection). Experimental conditions: Shodex Asahipak NH2P-50 4E 
(250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 4.75 and ACN (20:80); detection 
with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
3.4.1 Influence of different mobile phase composition on chromatographic separation 
Changes in mobile phase composition and its influence on the separation of fucose and other 
components in plasma sample was investigated. Mobile phase consisted of 5 mM Ammonium 
acetate (pH 4.75) and ACN (20:80) respectively, resolved fucose-spiked blank plasma sample 
without significantly changing the retention time of fucose as to when mobile phase consisted 
of water and ACN (20:80) was utilised. Increasing buffer composition so that the mobile phase 
consisted of 5 mM ammonium acetate (pH 4.75) and ACN (25:75) and (30:70) respectively, 
shortened elution time of fucose and other components and also increased the intensity of 
fucose peak. Fucose was observed to be eluted at around 6 minutes, approximately 1.5 minutes 
faster compared to when mobile phase containing ammonium acetate buffer and ACN with the 
composition of (20:80) was used. However, when blank plasma was subjected to analysis using 
both of these mobile phase compositions, a peak was observed suggesting a detectable 
compound but was not fucose despite its close retention time to fucose. Consecutively injected 
fucose solution and blank plasma confirmed this conclusion (figure 3.28 and 3.29). It can be 
Fucose peak 
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seen from both the chromatograms that the retention time of the compound observed in the 
injected blank plasma was 0.2 minutes shifted compared to the retention time of fucose. 
Another confirmation attempt was performed by injecting fucose-spiked blank plasma sample. 
Hence, we thought that with both mobile phase composition, fucose was probably interfered 
by other component in the plasma. This also suggested that the mobile phase consisted of            
5 mM ammonium acetate pH 4.75 and ACN with the composition of (25:75) and (30:70) 
respectively, could not be used. 
 
 
 
Figure 3.28 Normal phase-HPLC separation of solution containing fucose. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate    
pH 4.75 and ACN (25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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Figure 3.29 Normal phase-HPLC separation of blank plasma. Experimental conditions: Shodex 
Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 4.75 and 
ACN (25:75); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
  
In contrast, adjusting mobile phase to contain 5 mM ammonium acetate pH 4.75 and ACN with 
the composition of (15:85) and (10:90) respectively, increased retention time of fucose. Longer 
running time was also needed to completely elute the sample. The intensity of fucose peak and 
other detectable compounds was also decreased. This was similar to that observed when mobile 
phase consisted of only water and ACN was used as described under sub chapter 3.2. Thus, we 
decided to use mobile phase consisted of ammonium acetate buffer solution and ACN with the 
composition of (20:80) which gave optimum separation of fucose and other endogenous 
compounds. 
 
3.4.2 Influence of different pH value of Ammonium acetate solution on chromatographic 
separation 
It has been proposed that altering the pH of ammonium acetate solution in mobile phase to 
some extent will influence the ratio of non-protonated/protonated amine group in the column’s 
stationary phase. Therefore, the influence of this pH to the separation of fucose from other 
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compounds present in plasma was investigated. We limited pH selection of ammonium acetate 
solution to be in the range of its buffering capacity from 3.8 to 5.8. Three different pH values 
were chosen: 4.0, 4.75, and 5.0. The chromatograms obtained using a mobile phase consisted 
of 5 mM Ammonium acetate pH 4.75 and ACN (20:80) was used as reference to determine the 
influence of pH on fucose separation from other compounds present in plasma supernatant. 
Higher pH value of ammonium acetate was expected to shorten retention time, increase 
intensity and sharper fucose peak. On the other hand, increase in retention time, lower intensity 
and wider fucose peak was expected with lower pH value.  
 
Figure 3.30 shows chromatograms of fucose-spiked blank plasma samples containing 1 mg/mL 
of fucose. This is an overlay view of 6 chromatograms showing the samples eluted with mobile 
phase containing ammonium acetate solution with different pH (4.0, 4.75 and 5.0). It is clear 
from the chromatograms that fucose was eluted at similar retention time in all three tested pH 
value of ammonium acetate solution. The intensity of fucose peak was the highest when the 
pH value of ammonium acetate was adjusted to 4.75 and 5.0. However, this was not 
significantly different to when pH value of 4.0 was chosen, though the observed height of 
fucose peak was a bit shorter.  Thus, it can be concluded that changing pH value of ammonium 
acetate solution by 0.5 did not significantly change fucose retention time and peak intensity or 
height. The reason for this, we thought, probably because of the narrow gap between the tested 
pH values. The range of the tested pH values was not wide enough to produce significantly 
different ratio of non-protonated/protonated amine group in the column. We, therefore, decided 
to use ammonium acetate solution pH 4.75, the pH value at which its buffering capacity is the 
highest. 
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Figure 3.30 Normal phase-HPLC separation of fucose-spiked blank plasma (overlay view of six 
chromatograms). Experimental conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent 
containing 5 mM Ammonium acetate with three different pH value (4.0, 4.75 and 5.0)  and ACN (20:80); 
detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
3.4.3 Influence of different strength of Ammonium acetate solution on chromatographic 
separation 
Ammonium acetate solutions with different concentration (2.5 mM, 5 mM, 10 mM and              
25 mM) were used to determine the influence of its strength on the separation of fucose in 
fucose-spiked blank plasma samples. The pH of ammonium acetate solution was adjusted to 
4.75. Mobile phase consisted of each different strength of ammonium acetate solution and ACN 
(20:80) was used to elute fucose-spiked blank plasma sample. Mobile phase was allowed to 
run through the column for 1 hour to fully equilibrate the column.  We avoided using high 
concentration of ammonium acetate due to its low solubility in ACN which can probably cause 
precipitation in the column and, hence, disturb the sample elution. It was expected that as the 
strength of the buffer changed, change to the separation of fucose and other compounds in the 
sample would also occurred. Higher concentration of ammonium acetate in mobile phase can 
increase the retention of fucose and other components in the sample due to the increase of 
interaction between the compounds and ammonium acetate occupying column’s stationary 
Ammonium acetate pH 5.0 
Ammonium acetate pH 4.0 
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phase. However, we observed no change either in fucose retention time or its separation from 
other components in the plasma sample in the utilised different strength of Ammonium acetate 
solution. Therefore, we decided to use the lowest concentration, 2.5 mM ammonium acetate 
solution. This will lower the chance of immiscibility between the buffer solutions with ACN 
due to its low concentration. 
 
Up to this stage we concluded that mobile phase consisted of 2.5 mM ammonium acetate         
pH 4.75 and ACN (20:80) was appropriate to be utilised in resolving fucose-spiked blank 
plasma. 
 
3.4.4 Influence of altering Power Function and Filter value in CAD in improving linearity 
and resolution 
There are two parameters in CAD which can be adjusted to improve the appearance of a 
chromatogram in an analysis using CAD, namely: Power Function (PF) and Filter Value (FV). 
Power Function relates to manipulation attempt performed by the system of the instrument to 
produce better output using chromatographic data. However, this does not mean components 
separation profile in a sample is also changed107.  
 
A study has proven that several chromatographic parameters can be changed with the adjusted 
PF value107. Linearity is one such parameters which can be altered by changing PF value. 
Linearity, at a certain range of analysis, can usually be improved in a higher PF value. 
Similarly, higher PF value will also increase resolution between compounds. Increasing PF 
value will narrow an analyte peak-width which will then widen gap between compounds and 
hence improves resolution. Another change in a chromatogram appearance which can be 
observed due to this alteration in PF value is the signal to noise ratio. Relates to narrower peak 
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width and improvement in analytes resolution in a sample when higher PF value is used, this 
will also increase signal to noise ratio. Analytes peaks will appear to be sharper. This was 
similar to the result obtained in our study. While the detection correlation between the 
concentration of the sample and the area shown by the detector was suitably calculated in 
exponential manner at PF value of 1.0, this was no more valid with higher PF value of 1.5 and 
2.0. Lower correlation coefficient was obtained if exponential relation was kept. This created 
difficulties in choosing appropriate equation showing correlation between area and 
concentration of the sample if the particular PF value was selected. Whilst considerably good 
R2 was obtained in exponential manner when PF value was set to 1.0, neither linear nor 
exponential equation showed similar correlation coefficient at PF of 1.5 or 2.0.  
 
An equation which suitably correlate area in the chromatogram to the concentration of analyte 
is important to have perfect quantification of an analyte. Moreover, altering PF value also 
changed the area of the analyte. The system adjusted the area proportional to the selected PF. 
It was observed that higher PF gave lower area. It came to the result that at PF 2.0, the injected 
standard containing 10 ng of fucose gave area of 0.000. However, it is not necessarily be meant 
that the peak was not detected. In fact, fucose peak was still observed. Nevertheless, the area 
was not appropriately quantified due to limitation of minimum detected area can be shown by 
the instrument. Based on these two reasons, we decided to keep PF value at 1.0 with used 
exponential equation to quantify fucose based on its detected area. 
 
3.5 Digestion of fucoidan 
The method which can separate fucose from other endogenous substances present in plasma 
used Shodex Asahipak NH2P-50 4E column and mobile phase consisted of 2.5 mM 
Ammonium acetate pH 4.75 and ACN (20:80). The column compartment temperature was 30 
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°C and the autosampler compartment was 10 °C. Detection was performed using a CAD with 
PF and FV values set at 1.0 and 3.0, respectively. This method was intended to indirectly 
quantify fucoidan present in patients’ plasma. This was aimed to determine fucoidan 
concentration in plasma sample by quantifying the amount of fucose present in plasma samples 
taken before and after oral administration of fucoidan (187.5 mg four times daily) for 3 weeks. 
To do this, fucoidan must be degraded into its simplest constituting monosaccharides, 
particularly fucose. Hence, a digestion method was required to completely break down 
fucoidan into fucose.  
 
At this stage, the utilisation of 80% ACN was expected to completely precipitate plasma 
proteins. However, the recovery of fucoidan from plasma was yet to be evaluated. The 
digestion methods were tested with the consideration that the fucoidan could be completely 
recovered from plasma using 80% ACN. This implied that the most fucoidan would have been 
present in the supernatant. Therefore, fucose obtained after the tested digestion would be 
considered only obtained from the digested fucoidan. This is because no endogenous fucose 
was observed in the supernatant following precipitation using 80% ACN. 
 
 Digestion method using a 2 M TFA or 20% TFA was investigated. The performance of each 
method in digesting fucoidan into fucose was determined by comparing the amount of fucose 
obtained. A method yielded the most fucose was chosen. It has been reported that fucoidan can 
also be depolymerised using particular types of enzymes (e.g. fucoidanase). However, we 
preferred to use the chemical rather than enzymatic degradation because the chemical methods 
for the degradation of fucoidan have been well established and documented. Different types of 
fucoidanase enzymes are required for complete digestion of fucoidan. Also, such enzymes are 
not commercially available. These enzymes are reported to be produced by several types of 
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Gram Positive microorganisms. Therefore, we were required to first culture the different types 
of micro-organisms before even extracting the fucoidan degrading enzymes. The extracted 
enzymes then need to be purified as well as identified before employing them for fucoidan 
degradation. The candidate was expected to spend more than 12 months to accomplish the 
above mentioned steps. One of the aims of the study was the complete digestion of fucoidan. 
This could be achieved with the use of well-established chemical digestion procedures. 
 
3.5.1 Digestion of fucoidan using 0.2 M TFA 
Fucoidan was digested using 0.2 M TFA as described in 2.2.5.1. The amount of weighted 
fucoidan is shown in table 3.5. 
 
Table 3.5 The amount of weighted fucoidan for the determination percentage of fucose present in 
fucoidan after digestion of fucoidan using 0.2 M TFA 
Sample Name Weighted (Sample + 
container) (g) Container weight (g) Net weight (g) 
Fucoidan 1 0.1035 0.0865 0.0170 
Fucoidan 2 0.1041 0.0868 0.0173 
 
The amount of fucose yielded after digestion was calculated using a standard calibration curve 
obtained from the injected fucose standard solutions containing 5, 10, 25, 50 and 100 µg/mL 
of fucose (Figure 3.31). It was a quadratic equation with the formula of y = -9.718x2 + 375.22x 
- 8.7755, where y is the amount of the injected fucose in nanogram and x is the related fucose 
peak area. Correlation coefficient (R2) was 0.9999. 
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Figure 3.31 Standard calibration curve (peak area vs amount of fucose) using five injected fucose 
solution containing 5, 10, 25, 50 and 100 µg/mL of fucose 
 
The amount of fucose calculated from the two samples (injected in duplicate) are shown in 
table 3.6. The concentration of fucose in fucoidan was calculated by dividing the total amount 
of fucose by the initial amount of fucoidan and was shown in percentage values. 
 
 
Table 3.6 Percentage of fucose in fucoidan after digestion using 0.2 M TFA 
Sample Name Peak Area Amount of fucose (ng) 
Total amount 
of fucose (mg) 
Fucose percentage 
in fucoidan (%) 
Fucoidan 1a 1.1969 443.95 3.55 20.89 
Fucoidan1b 1.1932 442.65 3.54 20.83 
Fucoidan 2a 1.1025 410.64 3.29 18.99 
Fucoidan 2b 1.0422 389.27 3.11 18.00 
 
3.5.2 Digestion of fucoidan using 20% TFA 
Fucoidan was digested using 20% TFA as described in 2.2.5.2. The amount of weighted 
fucoidan is shown in Table 3.7. These were three fucoidan samples weighted separately and 
each sample was analysed in single injection. 
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Table 3.7 The amount of weighted fucoidan for the determination percentage of fucose present in in 
fucoidan after digestion of fucoidan using 20% TFA 
Sample Name Weighted (Sample + 
container) (g) Container weight (g) Net weight (g) 
Fucoidan 1 0.0847 0.0670 0.0177 
Fucoidan 2 0.0845 0.0672 0.0173 
Fucoidan 3 0.0848 0.0675 0.0173 
 
The amount of fucose obtained after digestion of fucoidan using 20% TFA was calculated using 
the same standard calibration curve used to determine amount of fucose after digestion of 
fucoidan using 0.2 M TFA. The percentage of fucose obtained is shown in table 3.8. 
 
Table 3.8 Percentage of fucose in fucoidan after digestion using 20% TFA  
Sample Name Peak Area Amount of fucose (ng) 
Total amount 
of fucose (mg) 
Fucose percentage 
in fucoidan (%) 
Fucoidan 1 1.1523 428.24 3.43 19.38 
Fucoidan 2 1.2059 447.12 3.58 20.63 
Fucoidan 3 1.2322 456.37 3.65 21.05 
 
Based on the data shown in table 3.6 and 3.8, it can be calculated that the amount of fucose 
obtained after digestion of fucoidan using 0.2 M TFA was 19.68% ± 1.42% (n=4), while that 
obtained after digestion using 20% TFA was 20.35% ± 0.87% (n=3). It can be concluded that, 
though it was not significantly different, the amount of fucose obtained after digestion of 
fucoidan using 20% TFA was a bit higher compared to that of digestion using 0.2 M TFA. 
Hence, 20% TFA was then used for the digestion of fucoidan. This value was also consistent 
to the values reported by Marinova, the manufacturer of fucoidan used in this study. 
 
3.6 Recovery of fucose from fucoidan-spiked plasma in conjunction with 
precipitation method 
Up to this point, we had chosen 80% ACN as the precipitating agent to precipitate plasma 
proteins. It has been tested that 80% ACN performed well in precipitating plasma protein as 
described in 3.3.3. Plasma proteins present in 1 mL of blank plasma could be precipitated with 
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4 mL of 80% ACN. Fucose and other endogenous substances present in supernatant obtained 
following precipitation of fucose-spiked blank plasma was resolved well with the 
chromatographic method using a mobile phase consisted of 2.5 mM ammonium acetate          
(pH 4.75) and ACN (20:80). The utilisation of 80% ACN should also yield high recovery of 
fucose from fucoidan. This because the expected analyte present in the plasma sample was 
fucoidan which, probably, has not been degraded into fucose. Therefore, the determination of 
the recovery of fucose from fucoidan in plasma, after precipitation of plasma protein using 
80% ACN was performed. Moreover, fucoidan was also tested to be less soluble in 80% ACN 
compared to that in MilliQ water. This was proven by a simple test: whilst 5 mg of fucoidan 
was completely dissolved in 5 mL of MilliQ water, precipitation was observed when it was 
dissolved in the same volume of 80% ACN. This would likely decrease the chance for fucoidan 
to be completely recovered from plasma using 80% ACN. 
 
The recovery of fucose was investigated after precipitation of fucoidan-spiked blank plasma 
has been performed. Fucoidan solution (1 mL) containing 10 mg of fucoidan was added into 
blank plasma (1 mL) or Milli-Q water (1 mL). Precipitation was then performed as described 
in 3.3.3. Fucoidan solution (1 mL) in Milli-Q water was used as control. Digestion using       
20% TFA was also performed to the dry samples obtained from the supernatant of both the 
sample and control as described in 2.2.5.2. The final solution was then subjected to HPLC 
analysis. The results are shown in Table 3.9. 
 
Table 3.9 Recovery of fucose from fucoidan-spiked blank plasma after precipitation using 80% ACN 
Sample name Fucose peak area Percentage recovery of fucoidan (%) 
Control 1 0.0090 Considered as 100% Control 2 0.0096 
Sample 1 0.0001 1.08 
Sample 2 0.0007 7.53 
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Based on the data shown in table 3.9, it can be calculated that the average peak area from the 
control samples was 0.0093 and the average area for the samples was 0.0004. This data shows 
that, as per the detected fucose peak area, recovery of fucose from fucoidan-spiked blank 
plasma after the performed precipitation using 80% ACN was very low (average of 4.30%, 
n=2). This was probably caused by the low solubility of fucose and fucoidan in 80% ACN. The 
addition of this precipitating agent probably caused fucoidan to precipitate along with plasma 
proteins. Hence, the small amount was recovered in the supernatant. This also suggested that 
fucoidan was precipitated, limiting the use of supernatant as the final sample due to low 
recovery of fucoidan.  Another option was to use other precipitating agents such as ethanol and 
acetone. However, fucoidan in ethanol or acetone was found to be insoluble as well.  
 
To overcome the above mentioned problems, we decided to analyse the precipitates obtained 
after precipitation of water or fucoidan-spiked blank plasma. Referred to the results obtained 
following precipitation using 80% ACN, fucoidan was expected to be mostly precipitated. 
However, since 80% ACN also contain around 20% of water which created chance for fucoidan 
to dissolve and went to supernatant phase, we decided to use pure ACN to precipitate plasma 
proteins as well fucoidan.  
 
3.6.1 Recovery of fucose from fucoidan-spiked blank plasma after precipitation using 
ACN 
In this test, fucoidan solution (200 µL) containing 1 mg/mL of fucoidan was added into a          
15 mL centrifuge tube containing blank plasma (500 µL). Precipitation using ACN was 
performed as described in 2.2.3.4. The precipitate was then subjected to digestion using         
20% TFA. We tried two different approaches in the way we use 20% TFA to digest protein 
precipitate and precipitated fucoidan (method 1 and method 2). In method 1, the digested 
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solution was evaporated to dryness and then Milli-Q water (1 mL) was added to the dry sample. 
In method 2, MilliQ water (3 mL) was added to the solution, vortex mixed and centrifugation 
at 3500 rpm for 20 minutes. The supernatant was carefully taken and then evaporated to 
dryness. Milli-Q water (1 mL) was then added to the dry sample. Final solution from method 
1 and method 2 was subjected to HPLC analysis to determine the recovery of fucose from 
fucoidan-spiked blank plasma. 
 
Table 3.10 shows the percentage of fucose recovered. The Recovery of fucose was calculated 
using the following equation. 
 

 − 

  100% 
 
Where ms was the amount of fucose from the sample, mb was the amount of endogenous fucose 
from blank plasma and mc was the amount of fucose from control. This also suggested, that the 
recovery of fucose was calculated based on the detected fucose area. The amount of fucose was 
calculated using the standard calibration curve as described in 3.5.1. 
 
Table 3.10 Recovery of fucose from fucoidan-spiked blank plasma after precipitation using ACN 
Sample Name Peak Area Amount of fucose (ng) 
Total amount of 
fucose (µg) 
Percentage 
recovery of 
fucoidan (%) 
Sample 1a 1.7464 634.42 63.44 93.21 
Sample 1b 1.7185 624.88 62.49 91.10 
Sample 2a 1.6961 617.22 61.72 89.41 
Sample 2b 1.6690 607.94 60.79 87.35 
Control 1 1.2059 447.12 44.71 Considered as 
100% Control 2 1.2322 456.37 45.64 
Blank 0.5531 213.34 21.33  
 
It can be seen from table 3.10 that the recovery of fucose from fucoidan-spiked blank plasma 
in method 1 was 92.16% ± 1.49% (n=2) and method 2 was 88.38% ± 1.45% (n=2). The results 
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indicated that the approach taken to analyse precipitates rather than supernatant gave much 
higher recovery (92.16%) compared to that of analysing the supernatant after precipitation with 
80% ACN (recovery of 4.30%). This also confirmed the suitability of ACN as the precipitating 
agent to precipitate both plasma protein and fucoidan. Furthermore, based on the result shown 
in table 3.10, method 1 gave higher recovery compared to that of method 2. Hence, this method 
was then validated according the guidelines provided by the International Conference on 
Harmonisation before applying it to analyse patients’ samples taken before and after oral 
administration of fucoidan.  
 
3.7 Method Validation 
The linearity estimated by correlation coefficient (r2) of a calibration curve for fucose peak 
(n=6) over a range of 5 to 100 µg/mL was greater than 0.994 over a period of 5 days. The assay 
performance was determined using a fucose peak. The intra- and inter-day precision relative 
standard deviations (RSDs) for fucose peak were less than 5.0% (n=6) and 3.5% (n=5), 
respectively. The intra- and inter-day accuracy RSDs were less than 4.6 and 4.0% respectively. 
The Intra- and inter-day retention time RSDs for fucose peak were less than 2.1% (n=6) and 
1.9% (n=5), respectively. The peak area (RSD) of fucose (n=5) investigated after slightly 
altering three of the chromatographic parameters (the strength of ammonium acetate buffer, pH 
value and mobile phase composition) was less than 5.0%.  
 
Limit of detection (LOD) and limit of quantitation (LOQ) of the method was investigated using 
the mean values of three calibration curves. The calculation was performed using the following 
formula for LOD = (3.3 σ)/S and for LOQ= (10 σ)/S; where σ is the mean standard deviations 
of the y-intercept and S is the slope of the curve. Limit of detection was calculated to be 2.28 
ng and limit of quantitation was 6.92 ng.  The reason for using high fucose concentrations was 
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due to the existence of endogenous fucose in patients as well as blank plasma samples.   Also, 
based on the polarity and size of fucoidan, it was predicted that the amount of endogenous 
fucose would be greater than the amount of fucose absorbed after oral administration of 
fucoidan.  Hence, the fucose standards were prepared in a way that that the fucose coming from 
the absorbed fucoidan can still be detected despite the existence of the endogenous fucose. 
 
Table 3.11 Summary of the result of the performed method validation 
 
The plasma supernatant containing fucose (n=5) was stored at -20 °C and the concentration of 
fucose was determined after 0, 7, 14, 21 and 31 days. The peak area of fucose in a sample 
stored at -20 °C for 0, 7, 14, 21 or 31 days was found to be 20.12, 20.98, 19.77, 21.06 or 20.66. 
These results indicated that fucose did not undergo degradation when stored at -20 °C for a 
period of 31 days.  
 
The chromatogram obtained from the analysis of water (blank), fucose standard solution in 
water (control), blank plasma and patient’s plasma sample is shown in figure 3.32, 3.33, 3.34 
and 3.35, respectively. 
 
 
 
The tested validation 
parameters Results 
Linearity (r2) > 0.994 Tested using calibration curve of fucose over a range 
of 5 to 100 µg/mL over a period of 5 days 
Precision   
 Intra- day RSDs < 5.0% n=6 
 Inter-day RSDs < 3.5% n=5 
Accuracy   
 Intra-day RSDs < 4.6%  
 Inter-day RSDs < 4.0%  
Retention time   
 Intra-day RSDs < 2.1% n=6 
 Inter-day RSDs < 1.9% n=5 
Peak area RSDs < 5.0% n=5 
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Figure 3.32 Normal phase-HPLC separation of water. Experimental conditions: Shodex Asahipak 
NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 4.75 and ACN 
(20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33 Normal phase-HPLC separation of fucose standard solution (control). Experimental 
conditions: Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium 
acetate pH 4.75 and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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Figure 3.34 Normal phase-HPLC separation of blank plasma. Experimental conditions: Shodex 
Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 4.75 and 
ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 Normal phase-HPLC separation of patient’s plasma sample. Experimental conditions: 
Shodex Asahipak NH2P-50 4E (250_4.6 mm), 5 µm; eluent containing 5 mM Ammonium acetate pH 
4.75 and ACN (20:80); detection with CAD, flow rate 1 mL/minute, injection volume 10 µL. 
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3.8 Patients’ samples analysis 
The developed method was utilised to determine the concentration of fucose in plasma samples 
obtained from healthy volunteers and from patients with breast cancer (pre- and post-
administration of oral fucoidan). The patients’ plasma samples were stored under -20°C, four 
weeks before the analysis was performed. All plasma samples were precipitated using ACN as 
described in sub chapter 2.2.3.4. The precipitates were then treated with 20% TFA to degrade 
fucoidan into fucose. The samples were then subjected to HPLC analysis using the developed 
method. Subsequently, the concentration of fucose was then calculated based on the detected 
peak area. 
 
 
 
 
Figure 3.36 Distribution diagram of fucose concentration in plasma sample from healthy volunteers and 
patients with breast cancer (before and after administration of fucoidan) 
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As shown in Figure 3.36, the fucose concentration ranged from 5.4 to 7.9 mg/100 mL in healthy 
volunteers with the mean value of (6.5 ± 0.74) mg/100 mL (n=10). The detected fucose was 
considered as endogenous fucose since healthy volunteers were not treated with oral fucoidan. 
This data was similar to a reported result in a study suggesting fucose level in a normal health 
control to be in the range of 3.42 to 9.05 mg/100 mL with an average value of 6.05 mg/100 mL 
108
. Another  study has reported the fucose levels in healthy subjects to be in the range of 4.3 
to 7.1 with an average value of 5.3 mg/100 mL109. 
 
Fucose levels were observed to be higher in plasma samples obtained from patients with breast 
cancer either pre- or post-administration of fucoidan compared to that of normal healthy 
volunteers. Fucose concentration ranged from 7.9 to 17.3 mg/100 mL with an average value of 
(12.8 ± 2.86) mg/100 mL in the patients’ plasma sample before the administration of fucoidan. 
Elevated plasma fucose levels in patients with particular pathological states such as breast 
carcinoma and other pathological states have been reported earlier108,110-119. It was also 
concluded that the rise in fucose concentration was free from particular type of illnesses since 
it was also found to occur in patients with tuberculosis and liver cirrhosis109. Therefore, the 
comparably high fucose levels in the plasma samples obtained from patients with breast cancer 
utilised in this study could be justified due to pathological condition of the patients. 
 
Figure 3.36 also shows the concentration of fucose in patients before and after administration 
of oral fucoidan. The average fucose concentration in all patients’ plasma samples was 
observed to be (13.9 ± 2.71) mg/100 mL or increased by 1.1 mg/100 mL (n=19) after oral 
fucoidan was administered. 
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Figure 3.37 The amount of detected fucose in mg/100 mL in each plasma samples from patients with 
breast cancer before and after administration of fucoidan 
 
Figure 3.37 shows the concentration of fucose before and after the administration of fucoidan 
in each patients’ plasma samples. It can be clearly seen that fucose concentration elevated in 
all but one patients plasma samples. The absorption of fucoidan and endogenous fucose 
metabolism in each patient was different. This can be observed by the different initial 
endogenous plasma fucose concentration between one patient to another and also the different 
values of elevated fucose concentration after oral fucoidan was administered. This also was 
probably the cause of the slightly (0.1 mg/100 mL) decreasing plasma fucose level shown in 
one patient after the administration of oral fucoidan.  Nonetheless, the overall result implies 
the consistency of the data obtained in this study. Therefore, it can be suggested that the 
administration of fucoidan has caused an increase in fucose concentration. This can also be 
interpreted that fucoidan was absorbed following oral administration. 
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The amount of the absorbed fucoidan was then calculated using the available fucose 
concentration from each patient’s plasma samples. Considering the initial endogenous fucose 
detected in plasma samples from patients with breast cancers differed to that of normal healthy 
volunteers; fucose level in the patients was then considered as the initial fucose level. This 
fucose concentration was used to subtract fucose concentration detected in the plasma samples 
from patients with breast cancer after administration of fucoidan. The amount of fucose 
obtained after this subtraction was considered as that came from the absorbed fucoidan.  
 
 
Figure 3.38 The percentage of the absorbed fucoidan in each plasma samples from patients with breast 
cancer before and after administration of fucoidan 
 
Figure 3.38 shows the percentage of the absorbed fucoidan. The value was obtained based on 
the amount of fucose in each patient’s plasma sample; referring to fucose concentration in 
fucoidan was 20.35% as described in sub chapter 3.5.2. Figure 3.38 clearly shows that fucoidan 
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was absorbed following oral administration. Based on the elevated fucose concentration, the 
total percentage of absorbed fucoidan was 14.28% (n=19). This value was higher compared to 
that reported in the earlier studies which suggested that fucoidan was absorbed by 0.6% and 
even lower by 100 to 1000 times as was claimed in another study63,81. This suggested that, 
despite its very polar, big molecule and highly negatively charged structure; to some extent 
fucoidan can be absorbed following oral administration. Moreover, it can also be concluded 
that the method developed in this study was proven to be appropriate for the determination of 
fucoidan in plasma samples. 
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Chapter 4 -  General Conclusion 
Fucoidan has been extensively studied for more than a decade for its potential pharmacological 
activities. It is currently available in the oral dosage form. However, the absorption of fucoidan 
after oral administration is currently unknown.  To our knowledge, there are only two studies 
that have investigated the amount of absorbed fucoidan after its oral administration. These 
studies have used an ELISA method to detect the fucoidan in plasma before and after its 
administration.  However, the validity of this method is questionable because of its potential 
cross-reaction with endogenous polysaccharides such as heparin and related endogenous 
molecules.  
 
In this study, we developed a new approach for the determination of fucoidan absorption after 
its oral administration. Considering high polydispersity and molecular weight of fucoidan, 
analysing fucoidan in its intact form is a laborious and time consuming process. On top of this, 
it is still not clear whether the fucoidan after its oral administration is absorbed without being 
structurally converted in the GIT.  Therefore, we decided to take an indirect approach to 
determine the absorption of fucoidan after its oral administration. This indirect approach 
involved the complete chemical degradation of fucoidan into fucose, its simplest structure-
constituting monosaccharide. This increased the specificity of the developed HPLC method 
since fucose is a single and well characterised molecule. Fucose also has, compared to that of 
fucoidan, a considerably low molecular weight (164.16 g/mol)120. Therefore, it eased its 
separation and detection in plasma sample. 
 
Among several different chromatographic methods tested in this study, fucose in blank plasma 
as well as patients’ plasma samples was well separated from other endogenous compound using 
a normal phase chromatography. The mobile phase consisted of 2.5 mM Ammonium acetate 
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(pH 4.75) and ACN (20:80) with the flow rate of 1.0 mL/minute. The column was a Shodex 
Asahipak NH2P-50 4E column and was kept in the column compartment under 30 °C. The 
samples were kept at 10 °C in the sample compartment and was injected in the volume of          
10 µL each time. Detection was performed using CAD with the particular set PF of 1.0 and FV 
of 3. Patients’ plasma samples were treated with ACN to precipitate plasma protein and 
fucoidan. The precipitate containing fucoidan was digested using 20% TFA. The performance 
of the developed HPLC method was also evaluated which showed acceptable intra- and inter-
day accuracy, precision and repeatability. This suggested the suitability of the method to be 
utilised for the determination of fucoidan in the patients’ plasma samples. 
 
Fucose concentration was obtained following determination of fucose in plasma samples from 
healthy volunteers, patients with breast cancer before administration of fucoidan and after 
administration of fucoidan; using the developed HPLC method. Fucose concentration in 
healthy volunteers was observed lower (6.5 mg/100 mL, n=10) compared to that of patients 
with breast cancer before administration of fucoidan (12.8 mg/100 mL, n=19). Increase in 
fucose concentration was also observed in patients with breast cancer after fucoidan was given 
which showed fucose concentration of 13.9 mg/100 mL (n=19). The amount of fucose 
concentration varied between patients but showed consistent elevation among them. This 
suggested that, with regards to the increase in the concentration of fucose, fucoidan was 
absorbed following its oral administration.  
 
Finally, this study has provided a new method and approach for the determination of fucoidan 
in plasma samples following its oral administration. The method offers simplicity compared to 
the available HPLC methods. For instance, the methods using fluorescence detector which 
require derivatisation of fucose to improve separation and detection. It also offers specificity 
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compared to the available ELISA methods which was suggested to have cross-reaction between 
the developed antibody and polysaccharides other than fucoidan. Also, the chosen chemical 
degradation of fucoidan will probably put the method to a lower cost and less time consuming 
compared to that of enzymatic procedure. The performance of the method has also been tested 
and showed acceptable result. The application of the method to the patients’ plasma samples 
has also been investigated and it can be concluded that fucoidan was absorbed after its oral 
administration. Further attempt, however, can be useful in investigating the mechanisms by 
which fucoidan is absorbed after its oral administration. 
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